

The background of the entire page is a photograph of several people, mostly women, wearing blue hats and dark blue t-shirts, participating in a tree-planting activity on a grassy hillside. One person in the foreground is holding a young tree sapling. The t-shirts have "Baxter VOLUNTARIO" printed on the back. The background shows a valley with a small town and distant mountains under a blue sky with scattered clouds. A semi-transparent blue geometric pattern is overlaid on the left side of the image.

Baxter

2025 Sustainability Report

💚 Sustainable Healthcare

🌍 Climate and Resiliency

👥 People and Communities

1. Formerly referred to as the Corporate Responsibility Report.

Introduction

Sustainability Pillars and Commitments

Sustainable Healthcare

Data Security and Privacy

Climate and Resiliency

Supply Chain Management

People and Communities

Community Investment

Sustainability Data and Disclosures



Letters from Our CEO and CSO

I am proud to lead Baxter and to share this year’s Sustainability Report on behalf of my colleagues around the world. As we shape Baxter’s next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while creating long-term value for all stakeholders.

Corporate responsibility and sustainability are integral to how we create that long-term value. We focus our efforts where we believe we can have the greatest impact: supporting patient care and access, the resilience of our operations and supply chain, and the well-being of our Baxter employees and communities worldwide. In 2025, we established our inaugural Chief Sustainability Officer role to strengthen governance, coordination, and accountability for this work across the enterprise.

Over the past year, Baxter has also continued to evolve. We’ve simplified our organization, activated the Baxter Growth and Performance System (GPS) to improve how we work every day, and renewed our focus on innovation for patients and customers. We are defining our path forward, sharpening execution and enabling teams to focus not only on what matters most, but on the cultural values that support us in doing so. Chief among those is that we care deeply for patients, customers, colleagues and communities, and that commitment is clear in the pages of this Sustainability Report.

In 2025, we made meaningful progress. Across our global operations, we advanced initiatives to improve manufacturing efficiency while reducing energy use and conserving water. We expanded renewable

energy capacity, including new solar installations and additional high-efficiency panels at key locations. We deepened collaboration with select healthcare partners to better understand barriers to care and advance best-practice approaches, including efforts to improve sepsis care. Our commitment to care is also reflected in long-term community partnerships, including the completion of a five-year collaboration with UNICEF to help protect and regenerate the aquifer serving Cali, Colombia. And notably, in 2025, Baxter and the Baxter Foundation contributed approximately \$32 million to communities around the world through strategic partnerships and product donations.

The progress captured in this report is the result of the dedication of my colleagues who bring our Mission to Save and Sustain Lives to life every day. Their commitment continues to drive Baxter forward and strengthen our ability to create lasting value for those we serve.



Andrew Hider
President and Chief Executive Officer

When I joined Baxter in July 2025 as the company’s first Chief Sustainability Officer, I was immediately struck by the culture that defines this organization: one grounded in care, collaboration, and an unwavering Mission to Save and Sustain lives. That purpose has guided Baxter for nearly a century, and it is our responsibility to help ensure that our mission continues to shape how we operate, innovate, and lead in a world that is rapidly changing around us.

Healthcare systems are under unprecedented pressure. Climate-driven disruptions, resource constraints, rising costs, and workforce challenges are reshaping how care is delivered. In this environment, sustainability is not a parallel agenda or a compliance exercise—it is essential to resilient healthcare delivery, enabling care teams to provide safe and reliable care for patients and communities.

Our newly created Sustainability team has assessed our industry, customer expectations and the evolving regulatory landscape in the markets we serve. Through a refreshed double materiality assessment that captures both our global impacts and the issues most critical to Baxter’s long-term success, we have identified the areas where we believe we can make the greatest difference across patient care, our operations and the broader value chain. This work has informed a new set of forward-looking targets designed to drive measurable progress and led us to three refined areas of focus: Deliver Sustainable Healthcare, Advance Climate and Resiliency and Champion People and Communities.

Across Baxter, our key priorities are brought to life each day. Through teams partnering with customers to expand access to care and improve outcomes, manufacturing teams strengthening supply chain resilience to ensure reliability for patients, and employees fostering a culture of safety and well-being. Together, these efforts reflect a simple but powerful idea: sustainability should enable care, not complicate it.

This year’s Sustainability Report highlights how we are advancing this work across Baxter while strengthening governance, transparency, and accountability. I am deeply grateful to our employees around the world for the care, expertise, and dedication they bring to this work. Together, we are sustaining the ability to deliver safe, reliable, life-saving care, today and for generations to come.



Renae Kezar
Chief Sustainability Officer


Company Profile²

At Baxter,³ we are everywhere healthcare happens, and everywhere it is going, with essential solutions in hospitals, physicians’ offices and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. Every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow and beyond.

We are driven to meet the needs of health systems, clinicians, and patients as we work to better address their diverse and critical needs. Our portfolio includes sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, advanced surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices.

Revenue by Segment⁴

(Continuing Operations)



Revenue by Product Category

2025



Company Overview

37.5^K
employees

350^{M+}
patients reached
each year

40+
manufacturing sites
worldwide

1.6^{M+}
connectable medical
devices support
patients globally⁵

100+
countries with Baxter
products

\$32^M
in charitable giving

2. As of Dec. 31, 2025.

3. References in this report to Baxter and “we,” “our” or “us” are intended to refer collectively to Baxter International Inc. and its U.S. and international subsidiaries.

4. Totals may not foot due to rounding.

5. Includes connected technology branded as Baxter, Hillrom, Welch Allyn, Mortara and BardyDx. Baxter data on file as of February 26, 2026.


2025 Highlights

A photograph of three young children of diverse backgrounds smiling and waving their hands. In the top left corner, the UNICEF logo is displayed. The text 'Five year partnership between Baxter Foundation and UNICEF' is overlaid in white. At the bottom left, it says 'Credit: UNICEF'.


unicef

Five year partnership between
Baxter Foundation and UNICEF

Credit: UNICEF

A close-up, slightly blurred image of a medical syringe with a blue plunger and a clear barrel, set against a dark background.

Baxter’s study on quantifying the
environmental benefits of OPAT
in the UK, in comparison to inpatient
administration of antibiotic therapy, was
published in Oxford Academic journal JAC

A wide-angle photograph of a large industrial water treatment facility. Several large circular fountains are spraying water into the air, creating a misty atmosphere. In the background, there's a large building and some trees under a clear sky.

137,000 m³ reduction in total
water consumption at our North Cove,
North Carolina site (vs. 2024)

A photograph showing a vast array of solar panels installed on a flat rooftop. The panels are arranged in neat rows, stretching towards the horizon. In the background, there are trees and some industrial structures under a clear sky.

746 kW state-of-the-art solar array
installed at our Toongabbie, Australia site

A circular badge with a gold border. Inside, it says 'BRONZE | Top 35%' in a gold banner, followed by the 'ecovadis' logo, 'Sustainability Rating', and 'AUG 2025'.

Baxter ranked in the top 35% of companies
globally through EcoVadis assessment

The Baxter logo in white, italicized font, centered on a dark blue background with a subtle geometric pattern of overlapping triangles.

Baxter



Sustainable Healthcare



Climate and Resiliency



People and Communities

Sustainability Pillars and Commitments



Our Sustainability Strategy

Focused, Aligned and Built for Action

In 2025, we took deliberate steps to assess how sustainability can best support Baxter’s purpose, business performance, and long-term resilience. Guided by our refreshed double materiality assessment (DMA),⁶ we sharpened our focus on the sustainability topics that matter most: those that sit at the intersection of patient impact, regulatory requirements, and value creation for the business. This marks a transition from our prior framework, with a clear shift from breadth to prioritization, from implementation to execution, and from standalone initiatives to value-chain impact. As sustainability becomes increasingly embedded in customer tenders, procurement decisions, and market access, focus is essential.

Anchored in What Matters Most

Our priorities guide commitments, resource allocation, and execution. We continue to focus on these areas in support of delivering against rising expectations from customers, regulators, and other industry stakeholders, reinforcing our role as a trusted partner to deliver sustainable healthcare.

Our refreshed approach reflects the growing expectation for product-level sustainability information, resilient supply chains, emission programs, and alignment with public-sector and health-system priorities. Priority sustainability issues, including sustainable products and packaging, climate, and water, extend beyond our direct operations, requiring action across the value chain.

A Foundation for What Comes Next

We are introducing four new forward-looking targets, aligned to our material priorities and designed to drive measurable impact. These targets replace our previous 2030 commitments and goals. Our sustainability strategy continues to support the United Nations Sustainable Development Goals (SDGs), with particular emphasis on advancing health and well-being (SDG 3), alongside water stewardship (SDG 6), responsible consumption (SDG 12), and climate action (SDG 13).



The following pillars and priority topics bring this strategy to life, translating focus from our prior 2030 commitments into action across our business and value chain.

Sustainable Healthcare

- Patient Safety and Product Quality
- Sustainable Products and Innovation
- Sustainable Packaging
- Data Security and Privacy

Climate and Resiliency

- Climate Change
- Water Stewardship
- Supply Chain Management

People and Communities

- Employee Experience
- Employee Health and Safety
- Community Investment

Targets:

Net-Zero

GHG emissions across Scope 1 and Scope 2 by 2050, in alignment with a 1.5°C science-based trajectory

100%

renewable electricity by 2040

80%

of supplier spend in priority categories have science-based targets by 2030

100^K

volunteer hours by 2031 (baseline 2026)

\$275^M

investment in underserved communities by 2030 (baseline 2021)

6. A DMA evaluates which topics are most significant based on both their potential impact on society and the environment and their financial relevance to the company.



Sustainable Healthcare

Patient Safety and Product Quality

Sustainable Products and Innovation

Sustainable Packaging

Data Security and Privacy

Delivering sustainable healthcare is core to our Mission to Save and Sustain Lives.

Every day, Baxter products support patient care across hospitals, clinics, and homes worldwide. As healthcare systems face increasing environmental, regulatory and resource pressures, our customers and stakeholders expect innovation that delivers clinical excellence with consideration of natural resource constraints.




2025 Sustainable Healthcare Highlights



Publishing study to quantify environmental benefits

Outpatient Parenteral Antibiotic Therapy (OPAT): OPAT uses a Baxter elastomeric pump to allow patients to have IV antibiotic therapy delivered to them in the comfort of their home or in an outpatient setting. In 2025, a Baxter study on quantifying the environmental benefits of OPAT in the UK, in comparison to inpatient administration of antibiotic therapy, was published. Under these conditions, the study showed that self-administered OPAT at home can reduce CO₂ emissions by up to 85%, a saving of 546 kg CO₂(e) per patient; cut water use by 78%; and reduce waste by 91% compared with inpatient IV antibiotic treatment. The results of this study were published in Oxford Academic journal *JAC—Antimicrobial Resistance* Volume 7, Issue 2.



Packaging innovation to reduce cold-chain reliance and extend shelf life

Hemopatch Hemostat: In 2025, Baxter launched Hemopatch Hemostat with smaller packaging and room temperature storage capability for the EU market, helping to improve accessibility in the operating room while eliminating the need for refrigerated transportation and storage.



Keeping materials in use through closed-loop manufacturing

Viaflex IV Bags: In 2025, we continued to execute our long-standing circular manufacturing practices for Viaflex containers, one of our highest-volume products. At certain U.S., Australian, and European sites, clean manufacturing scrap is reprocessed and reintegrated into Viaflex container production, helping to divert material from waste streams and reduce demand for virgin inputs.



Reducing life cycle energy and water use

Viaflo IV Containers: At the Sabinánigo, Spain facility, Baxter has implemented improvements for Viaflo products that helped to increase process efficiency, reduce energy consumption, and saved over 3,000 cubic meters of water per year.



Enhancing circularity by leveraging recycled materials

HR 900 Hospital Beds (NF Environnement Ameublement certified): Manufactured in Pluvigner, France, our HR 900 beds are made from at least 35% recycled materials, and many components are recyclable (where available). The plastic packaging for the beds is also recyclable (where available).

Sustainable Healthcare

Patient Safety and Product Quality

Our commitment to safety and quality is foundational to how we operate. We foster a culture of accountability for quality, reinforcing behaviors, standards, and controls that help protect patients and strengthen trust with customers and regulators.

We embed a quality mindset across the organization so that our employees are empowered to take ownership of the products and services we deliver. Operational excellence, disciplined execution, and adherence to regulatory requirements support our ability to produce high-quality products and drive sustainable performance. We aim to consistently strengthen our processes by integrating safety and quality throughout the product life cycle and by aligning with customer needs to build long-term trust and loyalty.

By strengthening our quality culture and executing innovative solutions to continually improve how we work, we remain focused on advancing patient outcomes, deepening our commitment to customers, and delivering strong, durable performance.

Sustainable Products and Innovation


Baxter’s approach to sustainable product innovation is rooted in a strong set of principles that have long been part of the company’s ethos; as Baxter continues to evolve our technology-enabled, patient-first healthcare portfolio, sustainable design principles are being scaled across the organization.

These sustainable design principles will serve as our comprehensive framework for embedding eco-design and circularity into product design, manufacturing, and use. We are focused on reducing environmental impacts across the product life cycle, from sourcing through end of life, while delivering on the quality, efficiency, and care needs of providers and patients.

Key enablers include life cycle assessment and product carbon footprint, which provide data-driven insights into environmental hotspots across a product’s life cycle and highlight key opportunities to reduce impacts related to materials and manufacturing processes.

Baxter’s approach to circularity promotes the efficient use of resources and keeping materials in use at their highest value for as long as possible. This includes reducing reliance on virgin materials, incorporating recycled or renewable inputs where feasible, reintegrating manufacturing scrap into production, and designing products and processes that support waste reduction and resource recovery.

Our technical service centers and field-based technicians support the management of our electromechanical medical devices by enabling maintenance, repair, refurbishment, reconditioning, and upgrades to extend the life of the product.



Access to Care

Access to care is increasingly shaped by the strength, adaptability, and foresight of the systems that deliver healthcare at scale. For Baxter, product innovation plays a central role in advancing access by designing solutions that help to strengthen supply continuity, perform reliably in high-risk environments, and adapt to the realities of global healthcare delivery. From pandemics and climate-driven disruptions to geopolitical instability, access-focused design and education help essential therapies reach patients when and where they are needed, while reinforcing trust with customers during periods of constraint or shortage.

2025 Highlights

- ➔ Baxter partnered with national health systems to develop a playbook aligned with the Rural Health Transformation Program funded by the U.S. government. Baxter’s Rural Health Playbook outlines solutions that can be used across the continuum of care, from diagnostics to enabling care in the home, and remote monitoring technologies.
- ➔ Baxter launched a focused effort with select U.S. health systems to better understand how to improve access to best-practice sepsis care, including convening roundtable discussions with key leaders to identify challenges and barriers.

Sustainable Packaging

Packaging plays a critical role in healthcare delivery. Sustainable packaging protects product safety and quality, and supports clinical use, while reducing environmental impact where possible. By considering packaging design, material choices, and end-of-life pathways through the lens of customer and patient needs, we aim to deliver sustainable healthcare without compromising the care patients rely on.

Where possible, we advance packaging solutions that incorporate recycled, renewable or recyclable materials, alongside innovative designs that optimize resource use and support circular economy principles.

Data Security and Privacy

Technology and the accelerating role of artificial intelligence (AI) are reshaping how healthcare can be delivered, creating new opportunities to improve efficiency, insight, and patient outcomes. Baxter approaches this evolution with a strong commitment to trust, privacy, and responsibility, prioritizing the protection of employee, patient, and customer data, the security of infrastructure and products, and the ethical use of AI across the organization.

We are responsibly integrating AI and machine learning into manufacturing operations and healthcare delivery solutions, aiming to improve efficiency, safety, and patient outcomes.

AI in Manufacturing and Supply Chain

By deploying an Industrial Internet of Things (IoT) platform, we analyze real-time data from sensor-driven systems to help detect anomalies, optimize processes, and enable predictive maintenance. We believe that this shift will help promote intelligent, self-correcting ecosystems that can adapt to disruptions such as natural disasters, labor shortages, or global health crises.

Policies, Positions, and Certifications

- [Global Privacy Policy](#)
- [Responsible Use of Artificial Intelligence Statement](#)





Climate and Resiliency

Climate Change

Water Stewardship

Supply Chain Management

Minimizing environmental impact and building resilient operations remain central responsibilities of our sustainability program. Our work is grounded in disciplined environmental standards and operational practices, integrated with our Global Manufacturing and Supply Chain teams and designed to minimize greenhouse gas (GHG) emissions and improve climate and water resilience.



Photo taken at our San Vittore facility

2025 Climate and Resiliency Highlights



Toongabbie, Australia: We installed a state-of-the-art solar array, which boasts a 746 kW solar panel installation, comprising high-efficiency panels designed to maximize energy production. This solar array is expected to generate significant savings, with an estimated annual reduction of more than 700 MT of CO₂ emissions. Since its commissioning, the solar array has been averaging a daily energy production of 2,542 kWh, with an annual estimated output of 928 MWh.



San Vittore, Switzerland: In 2025, we installed around 1,000 solar panels generating approximately 600 MWh of renewable electricity per year, which is directly consumed on-site. Additionally, the site achieved significant energy-efficiency improvements in 2025, through a combination of several projects including replacing oil-fired boilers with heat pumps.



Alliston, Ontario, Canada: The site reduced the frequency of sanitization cycles for all reverse osmosis loops. Rather than discarding sanitization water, the site now cools it back to ambient temperature for reuse, further reducing overall water withdrawal. This led to a water use reduction of approximately 36,000 cubic meters in 2025.



North Cove, North Carolina: The site reduced total water consumption by approximately 137,000 cubic meters (vs. 2024) through a combination of major process changes and targeted operational improvements. The elimination of distilled water bag rinsers through cleaner production methods resulted in a reduction of approximately 125,000 cubic meters of distilled water annually. Utility and process optimizations further supported overall water-efficiency performance.



Cali, Colombia: Baxter concluded a five-year commitment to protect and help regenerate the aquifer serving Cali, Colombia—an effort rooted in long-term stewardship and community partnership. The initiative centered on reforestation to strengthen watershed health, working with local stakeholders to help ensure the work reflected community priorities and needs. The efforts contributed to both ecological resilience and shared value in a region where water security is closely tied to community well-being.



UNICEF: For more than five years, UNICEF and the Baxter Foundation have collaborated to protect children and communities facing the challenges of limited access to safe water and a changing climate. With an investment of more than \$7 million, the Foundation has supported global disaster relief efforts and delivered essential water, sanitation, and hygiene (WASH) solutions—from climate-resilient systems for indigenous communities in Colombia to large-scale investments in Upper Egypt, reaching households, schools, and healthcare centers with safe water and sanitation services.

Climate Change

Roadmap to Net-Zero

Baxter is committed to achieve Net-Zero GHG emissions across our Scope 1 and Scope 2 by 2050,⁷ in alignment with a 1.5°C science-based trajectory. To support this pathway, we aim to source 100% renewable electricity by 2040.

Our Scope 1 and 2 emissions totaled approximately 262,000 metric tons of CO₂e in 2025, a reduction of over 7% year over year and 24.5% against our baseline year of 2020. Across our decarbonization effort we saved over \$2.6 million, including in cost avoidance, reinforcing the link between environmental performance and financial impact.

Baxter’s roadmap to Net-Zero is designed to be integrated into existing capital planning, energy management, and cost-reduction strategies, helping to ensure that decarbonization is achieved in a financially disciplined and operationally resilient manner.

7. Our Net-Zero by 2050 target covers Scope 1 and Scope 2 GHG emissions, calculated in accordance with the **GHG Protocol**, and excludes biogenic carbon dioxide emissions, which are reported separately.

Climate Resilience

Baxter’s approach to resilience is grounded in preparedness, flexibility, and continuity across our global manufacturing and supply network. Each year, our integrated supply chain team assesses projects that protect continuity of care by reducing climate- and water-related disruption risk at patient-critical manufacturing sites. We have increased mitigation activities, including improving structural integrity, working to ensure utility redundancy is in place, and enhancing overall site resilience and emergency response capabilities to address the impacts of severe storms. In 2025, Baxter invested nearly \$6 million across ongoing resiliency projects to reduce the risk of damage and business disruption due to flooding and high wind events including:



Strengthening Resilience

In North Cove, North Carolina, a multi-year levee improvement project was initiated in response to Hurricane Helene to strengthen resilient infrastructure at our facility, which is located alongside a river basin; we expect the project to expand existing protections and reduce the risk of flooding.



Advancing Independence

At select sites in Puerto Rico, solar energy and on-site generation are leveraged to significantly reduce reliance on the grid and strengthen resilience during extreme weather events.



Photo taken at our North Cove facility

Climate Action Roadmap

Our decarbonization roadmap is structured around a hierarchy of actions and annual planning targets designed to drive meaningful progress over time.

Together, these actions support our Net-Zero roadmap, making it actionable, measurable and embedded into how we manage energy and operational performance.

Reduction highlights for 2025

77

energy projects completed


4

energy assessments completed

Lean Energy Program⁸ performance across all manufacturing facilities implemented:

Prerequisite criteria	91%
Bronze criteria	77%
Silver criteria	71%
Gold criteria	54%

8. Through our Lean Energy Program, all of Baxter's manufacturing facilities can pursue advancement through four levels (Prerequisite, Bronze, Silver, Gold) by meeting criteria for program and technical requirements and standards of operational excellence.



Water Stewardship

Water is a vital resource in Baxter’s operations, a critical input across our product portfolio and essential to the communities in which we operate. Our approach to water stewardship is rooted in operational resilience, employee well-being, and shared responsibility with the communities where we operate.

In 2025 we reduced total water withdrawal by

4%

globally versus 2024, through a focused effort to reduce water intensity across global operations.

Water Stewardship Program Pillars:



Operational Resiliency

Ensuring continuity of operations at patient-critical sites remains a priority, particularly as water-related risks become more acute. The 2024 Hurricane Helene disruption at the North Cove, North Carolina, site reinforced the importance of strengthening preparedness and resilience at the facility level and our actions since underscore our commitment to adaptation across the organization.



Community and Partnerships

We work with nonprofit and local organizations and invest in community water initiatives that support resilience beyond our facility boundaries, including expanding access to clean water, improving water availability in schools and communities, and supporting water security.



Employee Well-Being

Water stewardship extends beyond operations to our stakeholders. We continue to direct our efforts toward minimizing the impact of water stress on our colleagues around the world, particularly in regions facing heightened scarcity, while advancing responsible water management practices at sites located in high-risk areas.



Supply Chain Management

Supply chain management plays a critical role in safeguarding product integrity, supporting operational resilience, and reducing our environmental footprint. This forms a strong foundation for collaborative supplier relationships and improving traceability from raw materials through finished goods.

As we advance our program, we will continue to focus on deepening partnerships, expanding primary data collection, and supporting suppliers in developing credible decarbonization pathways. We are committed to 80% of our supplier spend in priority categories having science-based targets by 2030. We are in the process of moving to activity-based accounting for our Scope 3 measurement.

Our sustainable supply chain program consists of four parts: carbon reduction, supply chain resilience, human rights and transparency, and responsible sourcing.

Carbon reduction: Purchased goods and services represent our largest category of Scope 3 emissions, underscoring the importance of supplier engagement through collaboration, data accuracy and transparency. As we advance our program, we will focus on deepening partnerships

and supporting suppliers in the development of science-based decarbonization plans.

Supply chain resilience: We continue to build flexibility, visibility, and rapid response capabilities, leveraging state-of-the-art technology, across our manufacturing, supplier, and distribution networks to protect patient care during events such as natural disasters, pandemics, labor disruptions and material shortages.

Human rights and transparency: Advancing Baxter’s Human Rights Assurance Program supports both customer expectations and evolving regulatory requirements related to human rights and environmental due diligence (HREDD). In 2025, we established program fundamentals using reporting mechanisms to help identify potential risks across the supply chain.

In 2026, efforts will focus on extending risk identification beyond Tier 1 suppliers through targeted engagement, including desktop assessments, documentation reviews, and audits. These actions should continue to strengthen the Human Rights Assurance Program and support readiness for future HREDD requirements.

Responsible sourcing: We partner with innovative suppliers to deliver high-quality products while advancing environmental, social, and ethical standards across the value chain.

- **Supplier assessment:** This commitment will be reinforced through functionality in our new e-Sourcing assessment tool. We continue to use the EcoVadis platform to conduct annual evaluations of participating suppliers’ performance, a key input for Baxter’s Preferred Supplier Program, which is set to launch in 2026. In our own EcoVadis assessment, Baxter ranked in the top 35% of companies globally and was awarded a bronze medal for sustainability performance.
- **Engaging with small businesses:** Through strategic partnerships with small business suppliers, our procurement spend becomes a contributor towards economic growth by supporting local jobs, generating earned income, and strengthening regional resilience. These partnerships help build communities and local economies where our suppliers live and work. Baxter’s 2025 small business spend generated \$327 million and directly supported \$95 million in employee income and more than 990 jobs.

Policies, Positions, and Certifications

- [EHS&S Policy](#)
- [Leadership in Energy and Environmental Design \(LEED\): Baxter has three LEED-certified sites](#)
- [ISO 14001:](#) More than 40 of our sites have been externally certified to ISO 14001
- [ISO 50001:](#) 15 of our sites have been externally certified to ISO 50001
- [Building Research Establishment Environmental Assessment Method \(BREEAM\):](#) Baxter has three BREEAM-certified sites
- [Global Human Rights Policy](#)
- [Global Supplier Standards Manual](#)
- [Code of Conduct](#)
- [Ethics and Compliance](#)

2025 Highlight

- ➔ In 2025, Baxter achieved a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC) in the categories of IV Solutions, Nutrition Solutions and Premix Drugs. Baxter’s recognition follows HIRC’s comprehensive and rigorous review of the company’s resiliency practices and supply chain.
- **Resilient global logistics, enhanced risk management and supply chain visibility:** Innovative tools provide real-time visibility into Baxter’s global distribution network, improving forecasting, enabling faster responses to emerging issues, and supporting accurate demand planning and risk mitigation.

- **Stronger cybersecurity frameworks:** With a proactive commitment to safeguarding critical operations, Baxter has established robust standard operating procedures to help protect the integrity of our supply chain.
- **Operational health and driving continuous improvement:** Baxter fosters a culture of continuous improvement worldwide through mission-driven employee programs, site-level improvement plans and ongoing investments in manufacturing.



People and Communities

Employee Experience

Employee Health and Safety

Community Investment

Baxter’s culture is shaped by our people and strengthened through their engagement, within the workplace and across the communities where we live, work and serve. We value employees not only for the impact they deliver every day, but also for the care, collaboration, and sense of purpose they bring to building a supportive, mission-driven environment.



2025 People and Communities Highlights



\$32 million donated

Baxter and the Baxter Foundation donated approximately \$32 million to communities through strategic partnerships and product donations, in support of our \$275 million by 2030 community investment goal.



Credit: Operation Smile

Communities in 98 countries

Baxter supported communities in 98 countries through financial investments, matching gifts, Dollars for Doers, scholarships, and product donations.



12,000 volunteer hours

Baxter employees recorded nearly 12,000 hours of volunteering.

Employee Experience

In 2025, we introduced Baxter Growth & Performance System (GPS). Baxter GPS is our operating system built on a simple foundation: People, Process, and Performance.



Baxter GPS guides how we work together to drive continuous improvement, reduce complexity, and better serve patients and customers. At the beginning of 2026, we rolled out Building the BEST Baxter, our refreshed enterprise framework bringing together our mission, vision, strategic focus, and Baxter GPS culture.

Company Culture

Our culture brings to life the values and behaviors that define how we work together, make decisions and show up for one another every day. We ground ourselves in three shared values: We Care, We Act and We Own. At Baxter, a strong employee experience is built on an inclusive culture and empowering people to grow, lead and stay connected to a purpose-driven mission.

At Baxter, we:

Care

deeply for patients, customers, colleagues, and communities.

Act

boldly to drive continuous improvement across all we do.

Own

our impact with the highest say/do ratio.

Nurturing Talent

Strong leadership and engaged managers are central to Baxter’s performance and culture. Through disciplined talent processes and targeted development programs, Baxter aims to strengthen leadership effectiveness and support career growth. Ongoing talent reviews help identify performance, potential, and risk, while programs such as Manager Fundamentals, which we expanded in 2025, equip new and first-time people managers with the skills needed to effectively lead and engage teams.

Employee Engagement

Employee engagement at Baxter is rooted in fostering connection and a shared sense of purpose in the workplace. This commitment is reflected in activities that support networking and professional growth, including leadership roundtables, cross-functional events, and family-friendly initiatives, such as Take Your Child to Work Day. Informal social gatherings and team-based activities further encourage collaboration and reinforce a culture of belonging.

Beyond the workplace, employees are supported in giving back through volunteerism and service initiatives and a variety of employee giving programs. These efforts include food and donation drives, environmental stewardship activities, seasonal giving programs, and volunteer events supporting veterans, families, and local nonprofit partners.

Health, wellness, and accessibility initiatives, such as community walks and disability awareness efforts, further reinforce a holistic approach to well-being and shared responsibility across the organization and the communities Baxter serves.

Learn more about [benefits](#) and [career development](#) at Baxter.

Inclusion and Diversity

A commitment to inclusion and diversity (I&D) is embedded in all we do at Baxter, including how we operate our business, develop and market our products, expand access to care and give back to our communities. Our I&D commitment influences our daily actions to help all feel seen, heard and valued, and enhances the experiences of our employees, customers and their patients.

At Baxter, our I&D strategy is grounded in behaviors – the everyday actions that shape how we work - and reinforced by structures, including bias-free internal and external policies, processes, systems and practices.

Our Business Resource Groups play an important role in fostering an inclusive culture and supporting employee engagement, connection and collaboration.

Scholarship Program

The Baxter Foundation established a global, merit-based scholarship program to assist the children of eligible Baxter employees who plan to continue their education in college or vocational school programs. Renewable scholarships are offered for full-time study at an accredited institution of the student's choice.

Since 1983, the program has awarded more than \$15 million in support of post-secondary education to more than 3,600 students across 50 countries.

A neutral third-party agency evaluates applications based on students’ academic, extracurricular, and employment accomplishments.

Employee Health and Safety

The health and safety of Baxter employees is fundamental to the integrity of the business and the reliability of our products. A strong safety culture is sustained through practices grounded in protection, well-being, compliance and operational resilience. Across the organization, employees are encouraged to speak up and contribute to a workplace where safety comes first and adaptability supports long-term performance.

Baxter’s Health & Safety programs are guided by a risk-based framework, establishing priorities for focused program improvement, risk reduction, corrective action planning and robust governance.

Part of this approach is our new Focus 8 program, which targets high-risk activities identified through more than 20 years of incident and compliance data. Focus 8 underpins site-level audits and reviews conducted using a risk-based escalation model, helping to ensure



that facilities receive oversight proportional to their risk profile. Focus 8 also serves as a core element of Baxter’s multiyear Start When Certain transformation, which aims to strengthen safety culture through people leader engagement, standardized procedures, and practical guidance for performing work safely.

BeWell@Baxter: Baxter supports employee health and well-being through a range of programs designed to encourage healthy habits and engagement. The BeWell program encourages healthy workplaces, along with wellness challenges, education on nutrition and physical activity, and annual flu vaccination campaigns, and helps promote well-being across the organization. Building on the program, in 2026 we plan to launch Wellable, our new digital wellness platform.

2025 Highlight

- ➔ Over the past four years, our Start When Certain train-the-trainer sessions have engaged more than 1,500 employees. This program encourages consistent safety practices globally by focusing on hazard identification, safety Gemba, and crucial safety conversations.



Community Investment

Giving back is central to Baxter. Through a comprehensive approach, we aim to improve health resiliency around the world through strategic partnership investments and product donations from Baxter and the Baxter Foundation (the Foundation). In 2025, product donations made up the largest share of our giving through our proactive, best-in-class manufacture-to-donate program, which supplied critically needed, long-dated products to support the missions of leading humanitarian partners.

In 2025, we evolved the Baxter Foundation’s work around three core pillars grounded in resiliency: access, community and opportunity.

- Access: We strengthen the backbone of care by investing in community health centers and healthcare workforce training and development.
- Community: We build communities ready to withstand crises through disaster preparedness and recovery partnerships, and water stewardship initiatives that help ensure communities have reliable infrastructure and public health systems before, during, and after a crisis.
- Opportunity: We invest in student achievement and teacher training to build science, technology, engineering and mathematics (STEM) learning environments. Our goal is to equip the next generation with the solutions they need to thrive as healthcare problem solvers and innovators.



Access

Investing in resilient health systems and workforce

Partner Spotlight

Direct Relief

Through the Transformative Innovation Awards, in 2025 Direct Relief awarded grants to five community health centers across the United States that help bolster the capacity of health workers to develop locally tailored curricula for their patients.



Credit: Tampa Family Health Center



Community

Building resource resiliency

International Medical Corps (IMC)

In 2025, the Foundation expanded its disaster relief commitment to IMC in support of their global disaster relief efforts. Since the start of the partnership in 2023, we have supported emergency preparedness and six different natural disasters across wildfires, hurricanes and typhoons.



Credit: International Medical Corps



Opportunity

Championing resilient STEM education systems

Northwestern University Baxter Center for Science Education (BCSE)

In 2025, the BCSE provided life science workshops and curriculum resources for high school and middle school teachers in the Chicago area. Since 2009, the program has reached more than 285,000 students.



Empowering Community Resilience: Our 100th Anniversary Campaign

In 2026, we launched Empowering Community Resilience — a global campaign that brings together how we support the communities where we live, work, and operate. Introduced as we approach the company’s 100th anniversary in 2031, the campaign elevates our philanthropic impact through Baxter and the Foundation via product donations, financial contributions, and the collective engagement of our global workforce, aiming to strengthen health resilience through service, partnership, and action.

A key element of the campaign is our 100 × 100 volunteer goal, mobilizing employees worldwide to contribute a combined 100,000 volunteer hours by our 100th anniversary. By investing our time, talent, and compassion, these efforts help build stronger, more resilient communities in the places our employees call home. Together, these efforts reinforce our commitment to people and communities, meaningful connections, shared responsibility, and long-term impact.

Policies, Positions, and Certifications:

- [EHS&S Policy](#)
- [ISO 45001](#): 30 of our sites have been externally certified to ISO 45001
- [Global Human Rights Policy](#)
- [World Health Organization Guidelines for Medicine Donations](#)
- [Partnership for Quality Medical Donations Guidelines](#)

Baxter

+

Baxter

FOUNDATION

EMPOWERING COMMUNITY RESILIENCE

All the ways #BaxterGivesBack



Baxter Employee
Giving & Volunteering



Baxter
Product Donations



Baxter Foundation
Grants & Employee Programs

Sustainability Data and Disclosures



This section of the Baxter 2025 Sustainability Report includes data and disclosures related to each of Baxter’s material sustainability topics (“Sustainability Data and Disclosures”). It also contains additional information that is relevant to Baxter and our stakeholders and important from the perspective of external sustainability reporting frameworks.

Table of Contents

About This Report	26
Reporting Frameworks	26
Scope of This Report	26
Assurance	26
Company and General Reporting Disclosures	27
GRI General Disclosures	27
Double Materiality Assessment	29
Financial Performance	30
Sustainable Healthcare	31
Patient Safety and Product Quality	31
Sustainable Products and Innovation	32
Data Security and Privacy	33
Climate and Resiliency	34
Climate Change	34
Water Stewardship	37
Supply Chain Management	38
Environment, Health, Safety and Sustainability Governance	40

People and Communities	41
Employee Experience	41
Employee Health and Safety	42
Community Investment	42
Governance	43
Management and Board Oversight	43
Product Stewardship	43
Human Rights	43
Waste Management	44
Ethics and Compliance	45
Political Contributions	46
Appendix	47
Policies and Standards	47
Transparency Statements	47
Independent Assurance Statement	48
Forward-Looking Statements	50

See our 2024 Corporate Responsibility Report for Baxter’s most recent [Task Force on Climate-related Financial Disclosures \(TCFD\) index](#).

About This Report

The Baxter Sustainability Report, previously referred to as the Baxter Corporate Responsibility Report, describes the company's policies, programs and performance across a broad range of sustainability topics.

Reporting Frameworks

To develop our sustainability reporting approach, we have considered the disclosure frameworks and guidance of leading sustainability standards and reporting organizations, including GRI (formerly known as the Global Reporting Initiative), the Sustainability Accounting Standards Board (SASB), the Task Force on Climate-related Financial Disclosures (TCFD), the United Nations Sustainable Development Goals and third-party raters and rankers focused on environmental, social and governance matters.

We have prepared this report with reference to the GRI Standards and the SASB Medical Equipment and Supplies Sustainability Accounting Standard (version 2023-12).

Scope of This Report

The performance and other data in this report is from calendar year 2025 unless stated otherwise. Some examples and program descriptions may include information from 2026, as relevant.

- This report covers Baxter's global operations, including subsidiaries, unless stated otherwise. Environmental, health, safety and sustainability data includes joint ventures where we have a controlling interest.
- This report presents sustainability data for Baxter's continuing operations following the divestiture of Baxter's Kidney Care business in January 2025. Sustainability data from 2023 and 2024 has been restated as needed to reflect continuing operations. Any significant restatements outside of material divestitures or acquisitions, as well as any data that includes divested operations or reflects a different reporting scope, are clearly identified where applicable.

- Our reporting boundary for greenhouse gas (GHG) emissions, energy, water, waste and employee health and safety data includes facilities where Baxter has operational control, including distributed offices, manufacturing facilities, research and development facilities, technical services and distribution centers, regardless of whether the location is owned or leased. This approach is consistent with the **Greenhouse Gas Protocol (GHG Protocol)**, developed by the World Resources Institute and World Business Council for Sustainable Development.
- All currency in this report is in U.S. dollars, unless stated otherwise.
- The methodologies, assumptions and estimates underlying our sustainability strategy, analysis and data continue to develop and are likely to continue to change in future periods, including as a result of regulatory or other developments or as a result of our ongoing strategic actions. As a result, the information we present in this report could differ from our prior disclosures, and information in future disclosures may differ from this report. We undertake no obligation to update any statement in this report or future disclosures except as required by law.
- Certain information in this report incorporates or otherwise relies upon data from third parties that we have not independently verified, and may be prepared in ways that are not consistent with our methodologies or practices.
- This report is intended for global use. Please consult the appropriate country-specific Baxter website for information regarding activities in that country.
- Some statements in this report about products or procedures may differ from the licensed indications in specific countries. Therefore, always consult the country-specific summary of product characteristics, package leaflets or instructions for use. For more information, please contact a local Baxter representative.

Assurance



Apex Companies, LLC (Apex) verified Baxter's Scope 1, 2 and 3 GHG emissions. See the related [verification statement](#). Apex also assured the introductory text and data in the following sections of the Sustainability Data and Disclosures section of this report. See the related [assurance statement](#).

- Sustainable Products and Innovation
- Climate Change (except the Separately Reported Emissions table)
- Water Stewardship
- Supply Chain Management (except SASB disclosures)
- Environment, Health, Safety and Sustainability Governance
- Employee Health and Safety
- Waste Management

Alignment with the GRI and SASB frameworks was not assured.

Select financial data is taken from the audited consolidated financial statements contained in the Baxter International Inc. [2025 Annual Report on Form 10-K](#). These financial statements are audited by Baxter's independent registered public accounting firm.

Company and General Reporting Disclosures

GRI General Disclosures

Baxter has reported the information in this document for the period Jan. 1, 2025, through Dec. 31, 2025, with reference to the GRI Standards. This includes GRI disclosures noted in the table at right, as well as other parts of this report. The information reported may meet in part or in full the requirements of each GRI disclosure listed.

GRI 2: General Disclosures 2021	External Framework	Detail
Organizational details	GRI 2-1	Baxter’s corporate headquarters is in Deerfield, Illinois, United States. Baxter International Inc. (BAX) is a publicly traded company listed on the New York Stock Exchange. Baxter 2025 Annual Report on Form 10-K
Entities included in the organization’s sustainability reporting	GRI 2-2	About This Report
Reporting period, frequency and contact point	GRI 2-3	Reporting period: January–December Frequency: Yearly Contact point: sustainability@baxter.com
Restatements of information	GRI 2-4	About This Report
External assurance	GRI 2-5	Assurance Statement
Activities, value chain and other business relationships	GRI 2-6	Baxter 2025 Annual Report on Form 10-K
Employees	GRI 2-7	Baxter had approximately 37,500 employees worldwide as of Dec. 31, 2025. Employee Experience Baxter 2025 Annual Report on Form 10-K
Governance structure and composition	GRI 2-9	Our Governance
Nomination and selection of the highest governance body	GRI 2-10	Corporate Governance Guidelines
Chair of the highest governance body	GRI 2-11	Our Governance
Role of the highest governance body in overseeing the management of impacts	GRI 2-12	Baxter 2025 Proxy Statement
Delegation of responsibility for managing impacts	GRI 2-13	Baxter 2025 Proxy Statement

GRI General Disclosures (continued)

GRI 2: General Disclosures 2021	External Framework	Detail
Conflicts of interest	GRI 2-15	Corporate Governance Guidelines Baxter Code of Conduct
Communication of critical concerns	GRI 2-16	Ethics and Compliance Baxter 2025 Proxy Statement
Remuneration policies	GRI 2-19	Baxter 2025 Proxy Statement
Annual total compensation ratio	GRI 2-21	Baxter 2025 Proxy Statement
Statement on sustainable development strategy	GRI 2-22	Our Sustainability Strategy (page 7) Baxter 2025 Proxy Statement
Policy commitments	GRI 2-23	Policies and Standards
Mechanisms for seeking advice and raising concerns	GRI 2-26	Ethics and Compliance
Compliance with laws and regulations	GRI 2-27	Patient Safety and Product Quality Environment, Health, Safety and Sustainability Governance Employee Health and Safety Ethics and Compliance
Membership associations	GRI 2-28	We engage with external organizations to help drive progress on a broad range of issues. Examples include the Advanced Medical Technology Association (AdvaMed), Association of Corporate Citizenship Professionals, Collaborative for Healthcare Action to Reduce MedTech Emissions, Healthcare Leadership Council, Healthcare Plastics Recycling Council, Medicines for Europe, MedTech Europe, National Association for EHS&S Management, Partnership for Quality Medical Donations, Pharmaceutical Supply Chain Initiative, Seramount, Sustainable Healthcare Coalition, US-ASEAN Business Council, U.S.-Ukraine Business Council, Vinyl Council of Australia and others.
Approach to stakeholder engagement	GRI 2-29	Baxter collaborates with a broad range of stakeholders—including communities, customers, employees, healthcare providers, industry associations, investors, nongovernmental organizations, patients and patient advocacy groups, payers, regulators/policymakers and suppliers—to understand their perspectives and inform how we address sustainability at Baxter. We routinely engage with our primary stakeholder groups, including through professional membership associations, to assess the sustainability topics that are most relevant to our business.

Double Materiality Assessment¹

To understand and prioritize topics that are important to the long-term sustainability of our business and most relevant to our stakeholders, we periodically conduct double materiality assessments (DMAs). These DMAs evaluate how Baxter’s business impacts the environment and society as well as how environmental, social and governance topics impact our results and financial position. These analyses (which may differ from those conducted for financial statement or other disclosure purposes) inform our sustainability strategy, commitment and targets.

In 2025, Baxter experienced several organizational changes, including the divestiture of our Kidney Care business and the appointments of a new Chief Executive Officer (CEO) and a new Chief Sustainability Officer (CSO), alongside broader shifts in the external sustainability landscape. In response, we conducted a refresh of our prior DMA to review the company’s material topics consistent with Baxter’s evolving priorities, business portfolio, leadership direction and sustainability governance. While maintaining continuity with the previous DMA, the refresh focused on strategic alignment with how sustainability considerations are embedded in Baxter’s business objectives.

The DMA refresh followed a four-phase process:

- **Understand:** Baxter revisited the company’s existing impacts, risks and opportunities (IROs) to confirm the continued relevance of material IROs. This included conducting a landscape analysis to capture evolving internal strategic and governance priorities, regulatory developments, peer benchmarking and stakeholder expectations.
- **Engage:** Through structured engagement with key stakeholders from across the business, led by Baxter’s CSO, we reviewed existing and new IROs, incorporating insights from diverse stakeholder perspectives to support a comprehensive assessment.
- **Prioritize:** IROs were then reassessed and refined based on stakeholder input. This resulted in a refreshed set of IROs and material topics.
- **Finalize:** Results were presented to a cross-functional group of Baxter’s management team members, the CEO and the Executive Leadership Team for validation. Afterwards, a refreshed set of IROs, a list of updated material sustainability topics and a double materiality matrix were finalized and shared with the Baxter International Inc. Board of Directors (the Board).

The updated material topics continue to be embedded into Baxter’s strategic priorities, goals, commitments and reporting roadmap, along with preparation for future DMAs as we refine our approach to incorporate evolving reporting requirements. We will continue to monitor internal and external developments as part of our approach to remain adaptive and forward-looking.

[GRI 3-1]

1. Our approach to the disclosures included in this report differs from our approach to the disclosures we include in other reports, including our filings with the U.S. Securities and Exchange Commission (SEC). For example, in this report, we are not using the terms “material” and “materiality” as defined for the purposes of financial and SEC reporting in the United States. Instead, the terms refer to environmental, social and economic topics that may be significant to our stakeholders and to the company, which we use to inform our sustainability strategy, priorities and goals, and reporting. The topics in the Material Topics table are listed in the order they appear in this report, grouped by sustainability pillars and governance. The listing within each category does not reflect the presumed importance or “materiality” of any particular topic to Baxter or our stakeholders.

● Priority Topics

● Other Material Topics

Sustainability Pillars	Material Topics	Descriptions
Sustainable Healthcare	● Patient Safety and Product Quality	Managing patient safety and product quality across the product life cycle through strong design, manufacturing, monitoring, reporting and leadership accountability to help meet patient needs and improve outcomes. Learn more.
	● Sustainable Products and Innovation	Embedding sustainable design principles and leading technologies into product development to improve sustainability across the life cycle, increase resource efficiency, reduce material use and enable circular design. Learn more.
	● Sustainable Packaging	Advancing packaging that uses recycled/renewable/biodegradable materials and is designed for recyclability, while reducing single-use packaging, volume and weight to support circularity. Learn more (page 11).
	● Data Security and Privacy	Protecting customers, patients and employees through cybersecurity and responsible data practices, including secure product development/manufacturing and compliance with evolving privacy- and artificial intelligence (AI)-related regulations. Learn more.
Climate and Resiliency	● Climate Change	Managing both our climate impact and our climate risks/opportunities by calculating and reducing emissions, optimizing energy, expanding use of renewables and strengthening adaptation and resilience planning. Learn more.
	● Water Stewardship	Managing operational impacts on water—withdrawals, consumption, quality, wastewater and stormwater—through efficiency, reuse/recycling, watershed protection and risk-based water strategies. Learn more.
	● Supply Chain Management	Selecting and managing suppliers to uphold Baxter policies and standards, using sustainability risk profiling, audits, surveys and other standardized tools to drive compliance and accountability. Learn more.
People and Communities	● Employee Experience	Investing in employee development and learning opportunities that enable career growth, strengthen capabilities and support long-term engagement and retention. Learn more.
	● Employee Health and Safety	Promoting workforce health and safety through occupational safety, support for well-being and mental health, and industrial hygiene practices across facilities and the supply chain. Learn more.
	● Community Investment	Partnering with communities through trust-based programs and investments, including cash, product donations and employee volunteerism to strengthen resilience and advance health access and education. Learn more.
Governance	● Waste Management	Managing nonhazardous, regulated, electronic and hazardous waste through reduction, recycling and safe disposal practices across operations and the supply chain. Learn more.
	● Ethics and Compliance	Upholding ethical business conduct and governance—including anticorruption, fair competition, compliance, transparency and responsible financial practices—across operations and the value chain. Learn more.

[GRI 3-2]

Financial Performance

At Baxter we manage financial performance by aligning our business strategy, portfolio management and capital allocation with our Mission to Save and Sustain Lives, supporting long-term value creation, financial resilience, and investment in innovation and sustainability priorities. Actions include driving operational excellence and efficiency; actively managing costs; investing in thoughtful innovation, automation and digitalization; and allocating resources to initiatives that enhance performance, expand patient access and support sustainable growth across markets globally. This approach is supported through enterprise-wide performance management processes, global operations and commercial teams, disciplined capital planning, and leadership oversight focused on continuous improvement and effective portfolio execution consistent with our strategic and operational plans. Financial performance is monitored through internal management reporting, performance metrics and regular review by senior leadership, which helps to enable timely decision-making and alignment with strategic, operational and sustainability objectives.

[GRI 3-3]

Disclosure Item	External Frameworks	2023	2024	2025	Detail
Net sales (\$ millions)	GRI 201-1	\$10,360	\$10,636	\$11,244	Baxter 2025 Annual Report on Form 10-K
U.S. net sales (\$ millions)	GRI 201-1	\$5,802	\$5,850	\$6,122	Baxter 2025 Annual Report on Form 10-K
International net sales (\$ millions)	GRI 201-1	\$4,558	\$4,786	\$5,122	Baxter 2025 Annual Report on Form 10-K
Net Income (loss) (\$ millions)	GRI 201-1	\$2,663	(\$638)	(\$957)	Baxter 2025 Annual Report on Form 10-K
Stock price (\$ at year end)		\$38.66	\$29.16	\$19.11	
Dividend (\$ per share)	GRI 201-1	\$1.16	\$1.04	\$0.52	Baxter 2025 Annual Report on Form 10-K
Research and development (\$ millions)	GRI 201-1	\$518	\$590	\$518	Baxter 2025 Annual Report on Form 10-K
Description of how price information for each product is disclosed to customers or to their agents	SASB HC-MS-240a.2				Baxter products are sold through contracts with customers, both within and outside the United States. Some of these contracts have terms of more than one year and place limits on our ability to increase prices; some contracts also specify minimum quantities to be purchased by the customer, and some contracts may include variable consideration related to rebates, sales discounts and/or wholesaler charge-backs. Our customers include hospitals, governments and other organizations. Both in and outside the United States, hospitals and other customers have joined purchasing entities, such as group purchasing organizations (GPOs), integrated delivery networks (IDNs) and public contracting authorities, to enhance purchasing power.
					See the Contractual Arrangements, Competition and Healthcare Cost Containment, Risk Factors and Revenue Recognition sections in Baxter's 2025 Annual Report on Form 10-K.
Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	SASB HC-MS-240a.3				Baxter does not disclose this data. See Contractual Arrangements in Baxter's 2025 Annual Report on Form 10-K for information about some factors that impact product pricing, including our contractual arrangements with GPOs and IDNs.

Sustainable Healthcare

Patient Safety and Product Quality

Baxter manages patient safety and product quality through an organization-wide framework that emphasizes compliance with regulatory expectations and supports the protection of patients, customers and other stakeholders. Quality practices are embedded throughout the full product life cycle, supported by standardized procedures, operational excellence and continuous improvement efforts that reflect evolving customer and patient needs. This approach is enabled through a global quality management system with defined governance, escalation pathways, cross-functional roles and responsibilities, and oversight of quality-related risks and controls. Effectiveness is monitored through risk management and quality system processes, performance metrics, issue identification and escalation, and regular feedback from customers, clinicians and patients to inform corrective and preventive actions.

[GRI 3-3]

[GRI 416-1]

Disclosure Item ²	External Frameworks	2025	Detail
Total recalls: medical device and drug products	GRI 416-2, SASB HC-MS-250a.1	37	In 2025, Baxter recalled or corrected approximately 4,896,000 units.
Recalls: medical device products	GRI 416-2, SASB HC-MS-250a.1	28	
Recalls: drug products	GRI 416-2, SASB HC-MS-250a.1	9	
Total regulatory inspections		209	
FDA inspections and enforcement notices			
Warning letters received		0	
FDA class I recalls ³		7	
FDA site inspections		9	
FDA-registered establishments available for inspection		50	
			As of Dec. 31, 2025, the MedWatch: The FDA Safety Information and Adverse Event Reporting Program database included two recalls, four corrections and two updates to alerts regarding recalls as follows:
			• Infusion Pump Correction: Baxter Issues Correction for Novum IQ Large Volume Pumps • Recall Alert: Baxter Permanently Removes Life2000 Ventilation System • Infusion Pumps Correction: Baxter Issues Correction for Novum IQ Infusion Pumps • Mobile Lift Component Recall: Baxter Healthcare Corporation Removes Mobile Lift Component due to Risk of Improper Attachment • Infusion Pump Correction: Baxter Updates Instructions for Use for Novum IQ Large Volume Pump due to Potential for Underinfusion • Update on Alert: Infusion Pump Issue from Baxter Healthcare Corporation • Update on Alert: Solution Set Issue from Baxter Healthcare Corporation • Continuous Ventilator Correction: Baxter Healthcare Corporation Issues Correction for Life2000 Ventilator due to a nonconforming battery charger, which triggers a battery alarm and renders the ventilator inoperable
			Note: One Vantive (former Baxter Kidney Care) product was also included when 2025 Baxter was searched:
			• Peritoneal Dialysis Set Correction: Baxter Issues Correction for MiniCap Extended Life Peritoneal Dialysis Transfer Sets Due to Risk of Patient Exposure to Higher Than Allowable Levels of Toxic Compound NDL-PCBA and/or NDL-PCBs

2. Due to divested operations, comparable data is not available for 2023 and 2024.

3. Differences compared with data on U.S. Food and Drug Administration (FDA) websites may be due to timeframe (the date Baxter takes an action may differ from the date FDA classifies that action), definition of "recall" (FDA data includes actions taken even if the product is not removed or corrected) or classification by product group vs. product code (FDA counts each impacted product code within a product family as a distinct recall).

Patient Safety and Product Quality (continued)

Disclosure Item ²	External Frameworks	2025	Detail
Number of fatalities associated with products	SASB HC-MS-250a.3		Under FDA regulations, manufacturers and device user facilities must report information that reasonably suggests a medical device may have caused or contributed to a fatality. Such reports for Baxter’s medical devices are available here: Manufacturer and User Facility Device Experience (MAUDE) Database .
Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	SASB HC-MS-250a.4		While these do not necessarily constitute enforcement actions, in 2025, Baxter received: • Seven Form 483s • One Site Inspection Classified Official Action Indicated (OAI) • Zero seizures • Zero injunctions See Patient Safety and Product Quality management approach text, as well as Certain Regulatory Matters in Baxter’s 2025 Annual Report on Form 10-K, for related information.

Sustainable Products and Innovation

Baxter manages sustainable products and innovation by applying sustainable design and circularity principles across product development, manufacturing, use and end-of-life. We use life cycle assessments (LCAs) and product carbon footprint analyses to guide material, design and process decisions that reduce life cycle impacts while maintaining quality, safety and regulatory compliance. This approach is supported through collaboration among our Research and Development, Engineering, Manufacturing and Sustainability teams, along with global chemical governance programs addressing materials selection, materials of concern and supplier engagement. Progress is monitored through use of life cycle data, materials-tracking systems, regulatory disclosures and product end-of-life initiatives, including recycling and refurbishment programs that support circularity.

[GRI 3-3]

[SASB HC-MS-410a.1]

Disclosure Item	External Frameworks	2023	2024	2025	Detail
Total amount of products accepted for take-back and reused, recycled or donated, broken down by: (1) devices and equipment and (2) supplies	SASB HC-MS-410a.2				See Sustainable Products and Innovation management approach text (at left) and the metrics below for information about the company's approach in this area and product-recovery data.
PVC and aluminum recycling programs for hospitals (Australia and New Zealand)	GRI 301-3, SASB HC-MS-410a.2				
Participating hospitals		231	303	281	
PVC collected for recycling (metric tons)		141	154	139	
Aluminum bottles recycled (metric tons)		2.5	2.9	2.6	

Data Security and Privacy

Baxter manages data privacy, cybersecurity and responsible AI with oversight from executives and the Board, supported by enterprise policies, standards and governance frameworks. Baxter monitors global regulatory developments and implements security, privacy and AI controls across our enterprise and products, including through secure product-development practices, third-party risk management and cybersecurity incident preparedness. This approach is supported by the Board and the Audit Committee of the Board (which has oversight responsibility with respect to certain cybersecurity incidents), Baxter’s Global Cybersecurity and Compliance team, cross-functional AI governance groups and mandatory employee training programs. Effectiveness is monitored through security testing, incident-response exercises, supplier risk assessments, employee training completion rates and customer-facing product security disclosures.

[GRI 3-3]

Baxter Digital Security Certifications

All information Baxter collects and uses is handled in a secure manner. We have obtained certifications for the following internal systems, products and services, based on the location of services and data involved.

Scope ⁴	Certifications and Alignment
Internal Systems	
Enterprise and internally developed systems environment	- These systems are formally aligned to and internally audited against Baxter’s Digital Security Controls Framework. - We strive to align our data-security controls with global regulatory requirements and with industry-standard control frameworks such as the National Institute of Standards and Technology Cybersecurity Framework 2.0 and the Secure Controls Framework. - Baxter’s cloud service providers and data center colocation providers are certified against multiple standards, including SOC 2 Availability certification.
Product deployment and support activities at Baxter’s Gloucester, UK, site, serving ICNet software and other digital products	ISO 27001 certification
Products	
Dose IQ Safety Software (on premise)	UL 2900 certification
ExactaMix Pro Compounder (on premise)	UL 2900 certification
Novum IQ Syringe Pump (on premise)	UL 2900 certification
Services	
Cardio Server ECG Management System	ISO 27001 certification
RetinaVue Network	HITRUST v2 validated
DeviceBridge Connectivity Platform	Application SOC 2 Type 2
BardyDx Ambulatory Cardiac Monitoring	Application SOC 2 Type 2

4. Not all products listed are available in all geographies, and proposed certifications for these products may be subject to change prior to regulatory approval or launch. Information in this table excludes Baxter’s Kidney Care business, which was divested in January 2025.

Climate and Resiliency

Climate Change

Baxter manages climate-related impacts by integrating energy efficiency, renewable energy use, decarbonization and climate resilience into operational planning, enterprise risk management, and global manufacturing and supply network strategies, with a new commitment to achieve Net-Zero GHG emissions for Scope 1 and Scope 2 from operations by 2050. Actions focus on reducing energy usage, expanding electrification, increasing renewable electricity sourcing and investing in decarbonization initiatives, some of which we are still working to identify. Baxter also strengthens climate resilience by maintaining business continuity plans at all facilities, implementing site-level measures to reduce exposure to extreme weather- and water-related risks and assessing projects that protect the continuity of operations at sites that manufacture patient-critical products. Site-specific energy and GHG-emissions assessments help us identify energy-conservation opportunities, such as implementing new technologies or adopting best practices, where appropriate. In addition to energy-efficiency initiatives, we work to decrease GHG emissions through cogeneration, electrification, on-site renewable energy systems and renewable electricity procurement. This approach is supported by enterprise energy management programs, cross-functional operations, our Supply Chain and Sustainability teams, capital planning and resilience-related investments. Progress is monitored through energy and GHG-emissions data, site-level climate- and water-risk assessments, tracking resilience and mitigation actions, supplier emissions reporting and climate-related disclosures aligned with TCFD. Through 2025, Baxter reduced Scope 1 and Scope 2 emissions by 24.5% compared with the 2020 baseline.

Additionally, Baxter aims to reduce Scope 3 emissions⁵ across our value chain, including through supplier engagement. Our Global Supplier Standards Manual outlines Baxter’s expectations for suppliers to operate responsibly and efficiently. This includes calculating and disclosing their GHG emissions from operations, including the portion attributed to Baxter.

[GRI 3-3]

Disclosure Item ⁶	External Frameworks	2023	2024	2025	Detail
Risks and Opportunities					
Financial implications and other risks and opportunities due to climate change	GRI 201-2				Baxter 2024 Task Force on Climate-related Financial Disclosures Index Baxter CDP Submission
GHG Emissions ^{7,8}					
Direct (Scope 1) GHG emissions ⁹ (metric tons CO ₂ e)	GRI 305-1	180,690	174,229	166,105	
Stationary sources (facilities) (metric tons CO ₂ e)		148,619	141,453	136,066	
Natural gas		121,552	122,661	116,471	
Fuel oil		10,385	4,807	5,081	
Propane and LPG		14,849	12,383	12,997	
Biomass ¹⁰		1,833	1,603	1,517	
Mobile sources (Baxter-owned vehicles) ¹¹ (metric tons CO ₂ e)		28,529	28,176	26,612	
Refrigerants ¹²		3,542	4,600	3,426	
Indirect (Scope 2) GHG emissions ¹³ (metric tons CO ₂ e)	GRI 305-2				
Location-based		216,771	195,902	186,458	

5. Baxter’s Scope 3 emissions relate to activities within the company’s value chain, but outside of our direct control. These emissions are based on various assumptions and estimates and are verified by a third party to a limited assurance level (see [verification statement](#)).

6. Data for 2023 and 2024 is updated from data reported in the Baxter 2024 Corporate Responsibility Report to reflect updated GHG-emission factors.

7. Apex verified to a reasonable level Baxter’s Scope 1 and Scope 2 emissions. Apex also verified to a limited level Baxter’s Scope 3 emissions. Some totals may vary from the sum of items in the category, due to rounding.

8. Totals do not include CO₂ emissions from Baxter-owned wood-fired boilers. See footnote 10 for further detail.

9. Baxter used the World Resources Institute and World Business Council for Sustainable Development’s **GHG Protocol** to calculate emissions data from fossil fuel use. We used country electricity emission factors published by the International Energy Agency and the Association of Issuing Bodies (for residual mixes), the U.S. Environmental Protection Agency (EPA) eGRID, the Green-e residual mix emission factors, the Australian National Greenhouse Accounts Factors and the Canadian National Inventory Report regional electricity emission factors to calculate GHG emissions related to electricity consumption.

10. GHG emissions from biomass fuel use (including wood and wood waste) were calculated in accordance with the **GHG Protocol** Corporate Accounting and Reporting Standard (Revised Edition). Emissions associated with the use of groundnut husk as fuel (reported in Scope 2) were calculated using emission factors from the U.S. EPA Center for Corporate Climate Leadership. Methane (CH₄) and nitrous oxide (N₂O) emissions from biomass combustion are included in reported Scope 1 and Scope 2 emissions, as applicable. Data for 2023 and 2024 is updated from data reported in the Baxter 2023 Corporate Responsibility Report and the Baxter 2024 Corporate Responsibility Report, for accuracy.

11. Baxter used the **GHG Protocol** to calculate GHG emissions associated with reported fuel usage by company-managed sales and distribution fleet vehicles and other vehicles. We estimated fuel usage for some international sales vehicles based on regional sales information.

12. Refrigerant emissions represent reported hydrofluorocarbon and other refrigerant losses by each Baxter location. We calculated associated GHG emissions using emission factors for each reported refrigerant.

13. Baxter used the World Resources Institute and World Business Council for Sustainable Development’s **GHG Protocol** to calculate emissions data from fossil fuel use. We used country electricity emission factors published by the International Energy Agency and the Association of Issuing Bodies (for residual mixes), the U.S. EPA eGRID, the Green-e residual mix emission factors, the Australian National Greenhouse Accounts Factors and the Canadian National Inventory Report regional electricity emission factors to calculate GHG emissions related to electricity consumption.

Climate Change (continued)

Disclosure Item ⁶	External Frameworks	2023	2024	2025	Detail
Market-based ¹⁴		123,741	108,338	96,198	
Total Scope 1 and market-based Scope 2 GHG emissions (metric tons CO ₂ e)	GRI 305-1, GRI 305-2	304,431	282,566	262,302	
Total Scope 1 and market-based Scope 2 GHG emissions intensity (metric tons CO ₂ e per \$ million of sales)	GRI 305-4	29.4	26.6	23.3	
Other indirect (Scope 3) GHG emissions ¹⁵ (metric tons CO ₂ e)	GRI 305-3	2,677,341	2,762,886	2,653,577	
Purchased goods and services (Category 1) ¹⁶		1,296,989	1,343,517	1,293,030	
Capital goods (Category 2) ¹⁷		173,192	167,439	198,041	
Fuel- and energy-related activities (Category 3) ¹⁸		76,618	70,793	66,342	
Upstream transportation and distribution (Category 4) ¹⁹		218,645	276,998	242,382	
Waste generated in operations (Category 5) ²⁰		16,833	17,229	16,586	
Business travel (Category 6) ²¹		31,083	30,165	21,264	
Employee commuting (Category 7) ²²		17,161	17,161	17,161	
Downstream transportation and distribution (Category 9) ²³		64,620	62,818	59,016	
Use of sold products (Category 11) ²³		534,044	522,973	496,482	
End-of-life treatment of sold products (Category 12) ²³		248,156	253,793	243,273	

14. Market-based Scope 2 electricity emissions reflect the use of renewable energy certificates (RECs) and other contractual instruments. In the reporting year, a portion of these instruments were not certified or otherwise may not have met all **GHG Protocol** Scope 2 Quality Criteria (including, for example, full alignment on vintage, or geographic specificity). While these instruments are included for transparency, the Company recognizes their possible limitations. Beginning in 2026, the Company will begin transitioning to purchasing certified RECs, Guarantees of Origin and other eligible Energy Attribute Certificates that meet **GHG Protocol** quality criteria.

15. For 2023, Scope 3 categories 1, 4, 6 and 7 include Baxter’s BioPharma Solutions business, which was divested in 2023. Scope 3 categories 8, 10, 13, 14 and 15 are reported in accordance with the **GHG Protocol** Corporate Value Chain Standard. These categories are not reported due to being immaterial. Emissions associated with category 8 (upstream leased assets) are included in Baxter’s Scope 1 and 2 emissions as they are under Baxter’s operational control. Baxter does not have significant processing of sold products (category 10), downstream leased assets (category 13), franchises (category 14) or significant investments (category 15). Data for 2023 and 2024 is updated from data reported in prior-year Baxter Corporate Responsibility Reports to reflect updated GHG emission factors.

16. Estimated based on global expenditures by category and emission factors from “Conversion factors kgCO₂ per £ spent, by SIC code 2022,” UK Government Department for Environment, Food & Rural Affairs (Defra).

17. Estimated based on capital expenditures and the machinery and equipment emission factor from “Conversion factors kgCO₂ per £ spent, by SIC code 2022,” Defra.

18. Estimated based on Baxter’s actual annual energy usage by energy type and GHG emission factors for each energy type per GaBi life cycle assessment software.

19. Estimated based on shipment of products to our customers using EcoTransIT World software, which is compliant with the **GHG Protocol** and the Global Logistics Emissions Council Framework. Excludes emissions from warehousing, which are included in Scope 3 category 1.

20. Estimated emissions for wastewater treatment by municipalities and off-site waste recycling and disposal based on Baxter’s waste generation by type, UK Government GHG Conversion Factors for Company Reporting and the U.S. EPA GHG Emission Factors Hub.

21. Estimated emissions from air travel, rental vehicles and hotel room stays provided by Baxter’s global travel providers. Also includes estimated emissions from personal vehicle mileage. Emission factors were obtained from UK Government GHG Conversion Factors for Company Reporting and U.S. EPA GHG Emission Factors Hub.

22. Estimated based on the rounded number of Baxter employees by country and statistics on commuting time and transport mode split into public transport, passenger cars, taxi and motorcycle, and walking or bicycling. Emission factors for each mode were obtained from Defra.

23. Estimated based on previous Baxter product LCAs as well as the company’s revenue by product type. Category 1 emissions were extrapolated to other categories depending on the product type.

Climate Change (continued)

Disclosure Item ⁶	External Frameworks	2023	2024	2025	Detail
Total GHG emissions footprint (Scope 1, 2 and 3) (metric tons CO ₂ e)	GRI 305-1, GRI 305-2, GRI 305-3	2,981,772	3,045,454	2,915,879	
Worldwide GHG emissions from product transport ²⁴ (metric tons CO ₂ e)		222,143	280,354	245,930	
Air Emissions ²⁵					
NOx and SOx emissions (metric tons)	GRI 305-7	402	271	238	
NOx		232	229	227	
SOx		170	42	11	
NOx and SOx emissions intensity (metric tons per \$ million of net sales)		0.039	0.025	0.021	
Energy ²⁶					
Energy usage from Baxter operations (thousand megawatt hours [MWh])	GRI 302-1	1,818	1,728	1,666	
Energy intensity (thousand MWh per \$ million of sales)	GRI 302-3	0.176	0.163	0.148	
Energy projects					
Energy savings (thousand MWh)	GRI 302-4	8.3	54.8	29.9	
Estimated CO ₂ e savings (metric tons CO ₂ e)	GRI 305-5	20,000	16,000	8,000	
Renewable energy (thousand MWh)	GRI 302-1	626	581	583	
Renewable energy (%)	GRI 302-1	34%	34%	35%	
Renewable electricity (thousand MWh)	GRI 302-1	337	318	323	
Renewable electricity (%)	GRI 302-1	58%	59%	62%	
Environmental Compliance					
Environmental notices of noncompliance	GRI 307-1	14	6	7	
Environmental fines paid (\$)	GRI 307-1	\$200	\$0	\$4,700	

24. Number includes Scope 3 emissions plus Scope 1 emissions for product transport.

25. Includes air emissions associated with on-site energy generation. Emission factors from the U.S. EPA publication "Compilation of Air Pollutant Emission Factors," AP-42, Fifth Edition, Volume 1: "Stationary Point and Area Sources." Some totals may vary from the sum of items in the category, due to rounding.

26. Data for 2023 and 2024 is updated from data reported in prior-year Baxter Corporate Responsibility Reports, as relevant.

Climate Change (continued)

Separately Reported Emissions	External Frameworks	2023	2024	2025
Direct CO ₂ biogenic emissions from the combustion of biomass not included in Scope 1 emissions above (metric tons CO ₂) ²⁷	GRI 305-1	107,797	94,271	89,245
Direct CO ₂ e emissions from the production of anesthetic gases not included in Scope 1 emissions above (metric tons CO ₂ e) ²⁸	GRI 305-1	2,246	2,497	2,220
Indirect CO ₂ biogenic emissions from the combustion of biomass not included in indirect (Scope 2) emissions above (metric tons CO ₂) ²⁷	GRI 305-2	n/a	4,888	8,874
Indirect CO ₂ e emissions from anesthetic gases not included in Scope 3 Category 11 emissions above (metric tons CO ₂ e) ²⁸	GRI 305-3	1,472,000	1,136,000	1,294,000

Water Stewardship

Baxter manages water stewardship as a critical responsibility by embedding it into operational resilience, employee well-being and the communities where we operate. Water-related risks are addressed through site-level risk management and resilience planning to support reliable operations and responsible water use. Actions focus on reducing water use, improving operational efficiency, strengthening preparedness for operational disruptions and water-related risks and vulnerabilities, and implementing site-specific water efficiency, wastewater management and resilience initiatives at priority manufacturing locations. As part of our water-risk management approach, we screened our full manufacturing footprint and identified 16 sites potentially exposed to water availability risks due to the incorporation of water into products or its use in critical manufacturing processes. These sites represent approximately 93% of our total water use (including water used in our products). Based on this assessment, we have developed site-specific improvement plans for each location. By the end of 2025, over 60 site-specific improvement actions had been implemented, representing approximately 40% of the targeted actions. This approach is supported through global water stewardship programs, collaboration across our Operations and Environment, Health, Safety and Sustainability teams, site-level action plans at priority facilities and engagement with local partners on community water initiatives. Progress is monitored by tracking water use and intensity data, site-level water-risk and resilience assessments, wastewater compliance monitoring and periodic reassessment.

[GRI 3-3]

Disclosure Item ²⁹	External Frameworks	2023	2024	2025
Water consumption ³⁰ (thousand cubic meters)	GRI 303-5	2,738	2,687	2,381
From sites in high-stress areas ³¹		268	247	232
From sites in extremely high-stress areas ³¹		149	157	118
Water withdrawal ^{32, 33} (thousand cubic meters)	GRI 303-3	7,839	7,432	7,112
From sites in high-stress areas ³¹		590	622	648
From sites in extremely high-stress areas ³¹		912	941	724
Water withdrawal intensity (thousand cubic meters per \$ million of sales)		0.76	0.70	0.63
Water discharge (thousand cubic meters)	GRI 303-4	5,486	5,171	4,740
Manufacturing sites located in high- or extremely high-stress areas ³¹ (%)		40%	42%	42%

27. GHG emissions from biomass fuel use (including wood and wood waste) were calculated in accordance with the **GHG Protocol** Corporate Accounting and Reporting Standard (Revised Edition). Emissions associated with the use of groundnut husk as fuel (reported in Scope 2) were calculated using emission factors from the U.S. EPA Center for Corporate Climate Leadership. Methane (CH₄) and nitrous oxide (N₂O) emissions from biomass combustion are included in reported Scope 1 and Scope 2 emissions, as applicable. Data for 2023 and 2024 is updated from data reported in the Baxter 2023 Corporate Responsibility Report and the Baxter 2024 Corporate Responsibility Report, for accuracy.

28. Beginning in reporting year 2025, we have separately reported direct CO₂e emissions associated with direct production of our anesthetic gases, which include HFE-236ea2, CHF₂OCHF₂CF₃ (Desflurane); HCFE-235da2, CHF₂OCHClCF₃ (Isoflurane); and HFE-347mmz1, (CF₃)₂CHOCH₂F (Sevoflurane). These direct emissions have not been assured by Apex. Beginning in the Baxter 2023 Corporate Responsibility Report, we separately reported indirect CO₂e emissions from the Use of Sold Products category. These indirect emissions have been assured by Apex. These indirect CO₂e emissions are a conservative estimate as they assume 100% release to atmosphere and do not account for hospitals that utilize gas capture or the metabolism of the gases by patients. For both direct and indirect emissions, this is consistent with the **GHG Protocol**: A Corporate Accounting and Reporting Standard (Revised Edition), the **GHG Protocol**: Corporate Value Chain (Scope 3) Standard and the **GHG Protocol** Accounting and Reporting Standard Amendment. Data for 2024 is updated from data reported in the Baxter 2024 Corporate Responsibility Report, for accuracy.

29. Data for 2023 and 2024 is updated from data reported in prior-year Baxter Corporate Responsibility Reports, as relevant.

30. Water consumption from Baxter’s 38 manufacturing sites with the most significant water usage, representing 98% of the company's total annual water usage in 2025.

31. Water-stress classifications are determined in accordance with the World Resources Institute Aqueduct Water Risk Atlas (version 4.0).

32. In Baxter’s 2024 Corporate Responsibility Report, “Water usage” was used for this metric. This year, the report uses the term “water withdrawal” to align with GRI 303: Water and Effluents 2018: “Sum of all water drawn from surface water, groundwater, seawater, or a third party for any use over the course of the reporting period.”

33. Water withdrawal from Baxter’s 38 manufacturing sites with the most significant water usage, representing 98% of the company's total annual water usage in 2025.

Supply Chain Management

Baxter manages supply chain operations by integrating resilience, responsible sourcing, transparency, supplier engagement and Scope 3 emissions reduction into procurement and supplier management processes. Actions include strengthening supply chain resilience and visibility, advancing responsible sourcing and human rights assurance programs, assessing supplier performance and engaging suppliers to address GHG emissions, particularly across Scope 3 Category 1 (Purchased Goods and Services). This approach is supported through cross-functional collaboration across our Procurement, Supply Chain, Supplier Quality and Environment, Health, Safety and Sustainability teams, along with supplier standards, assessment programs and analytics combined with digital tools and third-party platforms for risk management. Progress is monitored through supplier risk and sustainability assessments conducted through the **EcoVadis** platform, assessments and corrective action plans, GHG-emissions data collection, regulatory transparency reporting and ongoing review of supplier compliance with Baxter’s Global Supplier Standards Manual.

[GRI 3-3]

Disclosure Item ³⁴	External Frameworks	2025	Detail
Baxter suppliers participating in supplier sustainability survey (EcoVadis) ³⁵		2,124	
Participating suppliers with Good or Outstanding scores in Labor and Human Rights category (%)	GRI 414-2	90%	
Participating suppliers with Good or Outstanding scores in Environment category (%)	GRI 308-2	82%	
Baxter suppliers evaluated in supplier sustainability risk profile tool (EcoVadis IQ) ³⁶		19,337	
Baxter suppliers evaluated as Medium or Low risk in Labor and Human Rights category (%)	GRI 408-1, GRI 409-1	92%	
Baxter suppliers evaluated as Medium or Low risk in Environment category (%)		89%	
Spend with small businesses (United States) ³⁷ (\$ millions)	GRI 201-1	\$250	
Economic impact of spending with small businesses (United States) ³⁷	GRI 203-2		
Direct: Employee income (\$ millions)		\$56	
Direct: Jobs		607	
Percentage of (1) entity’s facilities and (2) Tier 1 suppliers’ facilities participating in third-party audit programs for manufacturing and product quality	SASB HC-MS-430a.1		In 2025, approximately 30% of Baxter’s total facilities worldwide completed third-party audits based on ISO 13485 (including through the Medical Device Single Audit Program) or ISO 9001; approximately 40% completed ministry of health or equivalent audits (depending on location) related to manufacturing and product quality; and approximately 10% completed safety marking (such as Conformité Européenne [CE]³⁸) audits. As of Dec. 31, 2025, approximately 25% of Baxter’s Tier 1 suppliers had obtained third-party certification. See Patient Safety and Product Quality and Supply Chain Management text (at left) for related information.

34. Due to divested operations, comparable data is not available for 2023 and 2024.

35. The performance categories presented in this table align with the **EcoVadis** methodology. “Outstanding” indicates a structured and proactive sustainability approach; policies and tangible actions on major topics with significant sustainability reporting. “Good” indicates a structured and proactive sustainability approach; policies and tangible actions on major topics with basic sustainability reporting. Data reflects suppliers participating in Baxter’s supplier sustainability survey program as of Jan. 31, 2026. A minor subset of suppliers with small businesses of 25 employees or fewer do not receive a score.

36. The risk categories presented in this table align with the **EcoVadis** methodology. Risk levels are based on 1) inherent risk, which is the sustainability risk of a company based on its industry and country or **EcoVadis** rating and 2) procurement risk, which is based on Baxter spend data.

37. Excludes data from Puerto Rico, which will not be available until late 2026.

38. CE marking appears on products traded on the extended single market in the European Economic Area and other applicable jurisdictions.

Supply Chain Management (continued)

Disclosure Item ³⁴	External Frameworks	2025	Detail
Description of efforts to maintain traceability within the distribution chain	SASB HC-MS-430a.2		As required by pharmaceutical and medical device regulations around the world, Baxter has identified basic requirements within the quality management system to help ensure traceability of materials used in the manufacturing process and finished goods are uniquely identifiable throughout the product supply and distribution chain. • Traceability of materials from suppliers to Baxter for use in the manufacturing process is managed by maintaining agreements and specifications with suppliers that define product-identification requirements. These unique part numbers are incorporated into production records so that all parts are traceable from receipt to release of finished product. In most manufacturing processes, electronic verification systems are utilized to help ensure the correct materials are used. • Medical device and pharmaceutical products manufactured by Baxter that require product registration and classification are labeled with a unique identifier that is traceable from the manufacturing process to the customer and may utilize barcoding and/or serialization technology to facilitate electronic track-and-trace capability. Enterprise resource planning systems are used to manage traceability to the point of sale. Baxter has business agreements with our wholesalers to help maintain traceability within their distribution chains. The product traceability information can be retrieved as needed. • Baxter maintains a range of compliance-focused initiatives such as Medical Device Regulation and unit-level serialization for drug products to enable track-and-trace capability to help ensure compliance to programs such as the European Union’s Falsified Medicines Directive and the FDA Drug Supply Chain Security Act. There are currently 21 countries/markets that have active compliance targets for drug product unit-level tracking. Procedures are in place to define traceability requirements through the product-development process to the end customer. For supplier-related requirements, see our Global Supplier Standards Manual for more information.
Description of the management of risks associated with the use of critical materials	SASB HC-MS-430a.3		See Baxter’s Position Statement on Conflict Minerals and our most recent Conflict Minerals Report .

39. For ISO 14001, 45001 and 50001 certifications, in 2025 we accounted for 28 manufacturing locations. The balance of 17 ISO-certified sites in 2025 comprises compounding locations (seven), offices (six), planning and fulfillment (three) and research and development/engineering (one).

People and Communities

Employee Experience

Baxter manages talent development and the overall employee experience by embedding engagement, professional development and leadership effectiveness into our workforce and people management practices across our global operations. Actions include targeted recruitment, continuous learning and development programs, leadership and manager capability building, regular employee engagement surveys and initiatives that support health, well-being, inclusion and career growth. This approach is supported with structured talent management and succession-planning processes, learning platforms and development programs, manager training initiatives, employee engagement mechanisms and oversight by senior leaders, who report to the Board’s Compensation and Human Capital Committee, as appropriate. Effectiveness is monitored through employee engagement surveys, talent review and planning processes, manager feedback and follow-up actions, workforce data analysis and periodic reporting to senior leadership and the Compensation and Human Capital Committee. Learn more about [benefits](#) and [career development](#) at Baxter.

[GRI 3-3]

Disclosure Item	External Frameworks	2023	2024	2025	Detail
Global workforce, by job level (as a % of total)					
Vice president and above		0.3%	0.3%	0.3%	
Director		1.7%	1.7%	2.0%	
Manager		9.8%	10.2%	11.6%	
Professional ⁴⁰		27.2%	27.6%	28.6%	
Technical/clerical ⁴¹		61.1%	60.2%	57.5%	
Global workforce, by region (as a % of total)					
Americas		54.2%	54.6%	64.6%	
Europe, Middle East and Africa		25.6%	25.0%	21.4%	
Asia Pacific		20.2%	20.4%	13.9%	
Employee voluntary turnover rate	GRI 401-1	12.8%	11.5%	11.5%	
Workforce representation data	GRI 405-1				The link below includes select Baxter hiring and voluntary exit demographic data and Baxter’s most recent EEO-1 disclosure. Certain Employee Demographic Data
Average training hours per employee/contractor ⁴²	GRI 404-1	29	30	29	
Benefits provided to full-time employees that are not provided to temporary or part-time employees	GRI 401-2				All benefits are generally provided to full-time and part-time employees. Benefits
Minimum notice periods regarding operational changes	GRI 402-1				Minimum notice period varies by country. The length of the notice period is dependent on the type of change being made. Baxter is committed to providing appropriate notice and follows all relevant consultation and notice requirements.
Programs for upgrading employee skills and transition assistance programs	GRI 404-2				Career Development

40. "Professional" includes individual contributors.

41. "Technical/Clerical" includes employees in operational and administrative/clerical roles.

42. This data includes training hours for employees and contractors, which include hours logged through Baxter’s global learning management system. Data for 2024 is updated from data reported in the Baxter 2024 Corporate Responsibility Report, for accuracy.

Employee Health and Safety

Baxter manages environmental, health and safety risks through a global management systems approach guided by our EHS&S procedures, with a focus on employee well-being, regulatory compliance and operational resilience. Actions include identifying and mitigating health and safety risks, updating high-risk procedures, and implementing hazard-identification and incident-prevention programs. They also include analyzing trends and root causes, as well as promoting a safety culture that prioritizes employee engagement and safe work practices. This approach is supported by defined EHS&S roles and responsibilities and cross-functional teams, as well as site-level audits and reviews, risk-based programs targeting high-consequence activities, and employee health and wellness initiatives, such as **BeWell@Baxter**. Effectiveness is monitored through safety performance data, incident and hazard tracking, corrective action management, risk-based audits, and regular reporting and review with senior leadership.

[GRI 3-3]

Community Investment

Baxter manages community investment through a coordinated approach led by Baxter and the Baxter Foundation, focused on strengthening health resilience in the communities where we operate through strategic grants and partnerships, product donations through our manufacture-to-donate program and employee engagement. Actions include financial contributions through long-term nonprofit partnerships, targeted product donations to humanitarian organizations and a patient assistance program, disaster preparedness and response support, and initiatives that advance healthcare access, clean water and science, technology, engineering and mathematics (STEM) education. This approach is supported by the Baxter Foundation through grant programs with trusted nonprofit partners, employee volunteer and matching-gift programs, and scholarship initiatives. Effectiveness is monitored through oversight of program implementation, review of partner activities, tracking of financial and product contributions, employee participation in volunteer and giving programs and periodic reporting on community impact. Learn more about how [Baxter Gives Back](#) to communities worldwide.

[GRI 3-3]

[GRI 203-1]

[GRI 203-2]

Disclosure Item	External Frameworks	2023	2024	2025
Recordable incident rate ⁴³	GRI 403-9	0.34	0.40	0.39
Employee/contractor severe injuries (total number)	GRI 403-9	6/0	14/0	10/0
Employee/contractor fatalities (total number)	GRI 403-9	0/0	0/0	0/0
Health and safety compliance				
Health and safety notices of violation settled		8	5	1
Health and safety fines paid (\$)		\$50,768	\$700	\$0

Disclosure Item ⁴⁴	External Frameworks	2023	2024	2025
Total charitable giving, by category (\$ millions)	GRI 201-1, GRI 203-1	\$46.30	\$38.21	\$33.58
Investments in underserved communities		\$40.69	\$31.54	\$32.36
Other charitable giving		\$5.61	\$6.67	\$1.22
Total charitable giving, by type (\$ millions)	GRI 201-1, GRI 203-1	\$46.30	\$38.21	\$33.58
Baxter product donations to aid organizations ⁴⁵		\$26.85	\$15.63	\$21.47
Business and facility cash donations		\$9.19	\$8.83	\$2.54
The Baxter Foundation contributions		\$10.26	\$13.75	\$9.57
Grants ⁴⁶		\$8.00	\$11.93	\$7.99
Matching gifts and Dollars for Doers		\$1.25	\$0.79	\$0.60
Scholarships		\$1.01	\$1.03	\$0.98
Scholarships awarded		349	350	333
Employee volunteer hours	GRI 203-2	13,700	12,300	11,800
Value of employee volunteer hours ⁴⁷ (\$)	GRI 203-2	\$459,000	\$428,000	\$426,000

43. Work-related injuries or illnesses requiring medical attention beyond first aid, including cases with days lost. All rates are based on 100 full-time employees working one year, which equals 200,000 work hours. For tracking purposes, Baxter follows U.S. Occupational Safety and Health Administration recordkeeping requirements worldwide. Supervised contractors are included in the injury statistics reported in this table and are not tracked separately. Independent contractors are not included in Baxter's injury data, because they are supervised by other organizations.

44. Data for 2023 and 2024 includes Baxter's Kidney Care business, which was divested in January 2025.

45. Includes product donations and Patient Assistance Program. Variations in Baxter's annual product donations are due to fluctuations in community needs, the need and volume of disaster relief response, the regulatory environment, product availability, manufacturing processes, changes in product mix and marketing. We identify opportunities to donate and respond to community and humanitarian aid partner requests as appropriate. Value of products donated (provided at no cost) is provided by nonprofit partners based on wholesale acquisition cost at the time of donation. This number may be greater or less than the value of Baxter products distributed during the year by our relief partners.

46. Contributions to U.S.-based 501(c)(3) organizations for programs within and outside of the United States.

47. Based on hourly rates of \$33.49 per volunteer hour for 2023, \$34.79 per volunteer hour for 2024 and \$36.14 per volunteer hour for 2025 (as of April 2026), as estimated by Independent Sector. Volunteer hours are self-reported by Baxter employees.

Governance

Management and Board Oversight

Sustainability matters receive strategic guidance and oversight at the highest levels of the company, including our Baxter International Inc. Board of Directors (the Board), the Compensation and Human Capital (CHC), Nominating, Corporate Governance and Public Policy (NCGPP), and Quality and Regulatory Compliance (QRC) Committees of the Board, CEO, CFO, General Counsel and certain of the direct reports of the CEO and certain other functional leaders.

Sustainability and corporate responsibility governance is organized through six councils (the Councils):

- Sustainable Products and Innovation
- Product Stewardship
- Environmental Sustainability
- Sustainable Supply Chain
- Sustainability Reporting
- Our People and Communities

The Councils are overseen by the Sustainability Leadership Team, which comprises cross-functional senior leaders as well as the chairs of each Council. The Sustainability Leadership Team convenes bimonthly to review Council progress, address new developments and track progress toward our refreshed sustainability commitments. An executive cross-functional steering committee (the Sustainability Global Steering Committee) provides direction and oversight regarding our sustainability initiatives and advances Baxter’s sustainability strategy and culture. The Sustainability Global Steering Committee meets or receives updates quarterly to monitor policies, action plans and strategies and other matters of significance

to our reputation as a socially responsible organization. The Chief Sustainability Officer and members of the Sustainability Global Steering Committee report out to the Executive Leadership Team, which includes the CEO and certain of the CEO’s direct reports, at least semiannually on sustainability matters. This includes updates on the progress of the sustainability strategy, annual sustainability goals and advancements toward long-term commitments.

In addition, the individual performance assessments of certain senior executives are based as an initial matter on our performance against pre-established measures for certain strategic priorities, including those related to corporate responsibility.

The Board plays a critical role in sustainability oversight. The Board receives updates at least annually on sustainability matters, including a discussion of related goals and industry trends and a report out on progress toward established commitments.

Product Stewardship

Our Product Stewardship team connects product safety, regulatory compliance, sustainability and supply chain resilience, helping to ensure that critical healthcare products are responsibly designed and reliably supplied.

In practice, the Product Stewardship team is responsible for:

Product safety and regulatory compliance

Working to ensure products meet global materials, chemicals and product regulations across all markets, working closely with R&D, Regulatory Affairs, Quality and Legal on related compliance and regulatory matters.

Chemical risk management

Identifying, assessing and mitigating risks associated with substances, raw materials and components, from design through end-of-life, including managing emerging regulations and restricting or substituting high-risk materials.

Embedding sustainability into product design and innovation

Partnering with R&D and Engineering to integrate sustainability considerations early in development, such as material efficiency and safer chemistries.

Transparent customer and stakeholder communication

Providing accurate, consistent product-level sustainability and materials information to healthcare customers, regulators and internal teams, supporting customer disclosures, audits, sustainability reporting and data transparency.

Baxter continues to partner with key industry groups spanning the medical devices and pharmaceuticals fields to address industry requirements, share best practices and monitor regulations. We are a member of AdvaMed U.S., MedTech Canada, MedTech Europe and Medicines for Europe among others.

Human Rights

Baxter respects human rights and has policies and processes in place to help protect those rights across our value chain. These include the rights of our employees, workers in our external supply chain, our customers and the patients who rely on our products. As outlined in our Global Human Rights Policy, we respect the human rights, dignity and diverse contributions of all individuals in alignment with the Universal Declaration of Human Rights.

Fostering human rights takes many forms at Baxter and is reflected in our policies and initiatives in areas including workplace inclusion, employee safety, supply chain labor practices, ethical conduct, access to healthcare, and patient, employee and customer privacy.

Protecting human rights in our supply chain

Baxter’s suppliers are expected to respect and comply with our Global Human Rights Policy in their own operations and in their supply base and business relationships wherever possible. The majority of our suppliers have adopted Baxter’s Global Supplier Standards Manual, which requires adherence to applicable human rights and fair working conditions laws of the United States and the country in which they operate.

Each year, Baxter provides transparency statements in response to legislation from Australia, Canada, Norway and the UK, among others, related to human rights and fair working conditions. We also have a position statement related to the California Transparency in Supply Chains Act and we publish an annual Conflict Minerals Report. Baxter continues to monitor the evolving global regulatory landscape regarding human rights reporting.



Waste Management

Baxter manages waste and materials impacts by integrating waste reduction and circularity considerations into product design, manufacturing and distribution, with the goal of maximizing material value across the product life cycle. Actions include conducting site-level waste assessments to identify reduction and circularity opportunities, prioritizing initiatives based on potential environmental and operational benefits and implementing practices that support material reuse, improved manufacturing processes and extended product and component lifespans. This approach is supported by global guidelines for circularity, cross-functional collaboration across our Operations, Engineering and Sustainability teams, and partnerships with suppliers and logistics providers to enable material recovery and reuse. Progress is monitored through site-level waste assessments, tracking of waste-reduction and reuse initiatives and evaluation of circularity opportunities across manufacturing operations and the broader value chain.

[GRI 3-3]

Disclosure Item ⁴⁸	External Frameworks	2023	2024	2025
Nonhazardous waste ⁴⁹ (metric tons)	GRI 306-3	45,524	45,368	46,521
Recycled		30,954	31,514	34,193
Incinerated with energy recovery		4,240	3,869	3,565
Incinerated		1,217	1,292	890
Sent to landfill		7,387	7,064	6,827
Other disposal		1,726	1,629	1,046
Hazardous waste ⁵⁰ (metric tons)	GRI 306-3	4,800	6,115	5,524
Recycled		469	821	430
Incinerated with energy recovery		793	650	961
Incinerated		1,163	848	680
Sent to landfill		457	1,556	1,353
Other disposal		1,918	2,240	2,100
Total waste ⁵¹ (metric tons)	GRI 306-3	50,324	51,483	52,045
Recycled		31,423	32,335	34,623
Incinerated with energy recovery		5,033	4,519	4,526
Incinerated		2,380	2,140	1,570
Sent to landfill		7,844	8,620	8,180
Other disposal		3,644	3,869	3,146
Nonhazardous waste diverted from landfill ⁵² (%)	GRI 306-4	77%	78%	81%
Hazardous waste diverted from landfill (%)	GRI 306-4	26%	24%	25%
Waste management at Baxter (% of total)	GRI 306-5			
Recycled		62%	62%	66%
Incinerated with energy recovery		10%	9%	9%

48. Data for 2023 and 2024 is updated from data reported in prior-year Baxter Corporate Responsibility Reports, as relevant.

49. Excludes production by-products reused on-site, construction and demolition debris, discarded manufacturing- and process-related machinery or equipment, wastewater and wastewater treatment sludge.

50. Excludes waste recycled on-site, remediation waste, construction and demolition debris, wastewater and wastewater treatment sludge. Includes certain waste streams (such as waste oils, batteries, fluorescent lamps, light ballasts and asbestos) not classified as regulated in some locations. Includes discarded/returned products (IV solution, dextrose solution, etc.) that are nonhazardous in nature but may be classified as regulated in some countries. Prior to 2025, Baxter reported this data as “regulated waste” in our Corporate Responsibility Reports. This year, it has been updated to “hazardous waste” to align with GRI 306-3: Waste.

51. Excludes construction and demolition debris, discarded manufacturing- and process-related machinery or equipment, remediation waste, wastewater and wastewater treatment sludge. Removing these waste categories from the company total allows for more consistent evaluation of facility performance and trends over time.

52. Includes recycling and incineration with energy recovery.

Waste Management (continued)

Disclosure Item ⁴⁸	External Frameworks	2023	2024	2025
Incinerated		5%	4%	3%
Sent to landfill		16%	17%	16%
Other disposal		7%	8%	6%

Ethics and Compliance

Baxter manages ethics and compliance through a global program grounded in integrity, personal accountability and adherence to applicable laws, regulations and international standards across our operations and value chain. Actions include maintaining and periodically revising our Code of Conduct and related policies, delivering mandatory ethics and compliance training to employees and relevant third parties, conducting risk-based compliance assessments and audits and managing third-party due diligence. This approach is supported by senior leadership engagement, the Chief Compliance & Trust Officer, global and local compliance committees, formal policies and procedures and a dedicated ethics and compliance function. The Chief Compliance & Trust Officer also reports periodically to the Board on ethics and compliance matters. Effectiveness is monitored through compliance assessments, data-analytics-based monitoring, audits, Ethics and Compliance Helpline reporting and investigations, disciplinary and remediation processes and ongoing review of risks related to ethics and compliance.

[GRI 3-3]

[GRI 205-1]

[GRI 205-2]

Disclosure Item ⁵³	External Frameworks	2025	Detail
Ethics and Compliance Helpline			
Total items reported		618	
Total cases closed		665	
Non-compliance with laws and regulations in the social and economic area	GRI 419-1		Baxter 2025 Annual Report on Form 10-K
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	SASB HC-MS-270a.1		In 2025, Baxter had no monetary losses due to legal proceedings associated with false marketing claims that were previously reported in any company Exchange Act filings.
Description of code of ethics governing promotion of off-label use of products	SASB HC-MS-270a.2		Off-label promotion is strictly prohibited at Baxter. See the Baxter Code of Conduct and the Baxter Global Interactions Policy . See Ethics and Compliance management approach text (left of table) for information about the company's approach in this area.
Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	SASB HC-MS-510a.1		In 2025, Baxter had no monetary losses due to legal proceedings associated with bribery or corruption that were previously reported in any company Exchange Act filings. See Ethics and Compliance management approach text (left of table) for information about the company's approach in this area.
Description of code of ethics governing interactions with health care professionals	SASB HC-MS-510a.2		See Baxter's Global Interactions Policy and Ethics and Compliance management approach text (left of table) for information about the company's approach in this area. Baxter has country annexes that outline additional restrictions and considerations when interacting with healthcare professionals in each respective country. Baxter has adopted the AdvaMed Code of Ethics and also belongs to similar industry and professional associations around the world. See Professional Codes of Ethics and Industry Standards on Baxter's Ethics and Compliance page for information.

53. Due to divested operations, comparable data is not available for 2023 and 2024.

Political Contributions

Baxter manages public policy and political engagement activities in compliance with applicable laws and regulations and in alignment with our Code of Conduct, which outlines principles governing participation in the political process. Actions include maintaining and enforcing policies related to public affairs and political activities, governing employee and corporate participation in the political process and overseeing political contributions, including annual reports on contributions made through the Baxter Political Action Committee (BAXPAC). This approach is supported by oversight from the Nominating, Corporate Governance and Public Policy Committee of the Board, along with internal governance processes and compliance controls. Compliance and transparency are monitored through internal review processes, and we publicly disclose political contributions in accordance with applicable reporting requirements. See our [2025 political contributions](#).

[GRI 3-3]

[GRI 415-1]

Policies and Standards

- Partnership for Quality Medical Donations Guidelines

- Responsible Use of Artificial Intelligence Statement

Transparency Statements

- California Transparency in Supply Chains Act Supplier Disclosure Statement



Independent Assurance Statement

To: The Stakeholders of Baxter International Inc.

Introduction and Objectives of Work

Baxter International Inc. (Baxter) engaged Apex Companies, LLC (Apex) to provide assurance of selected disclosures and metrics included in Baxter’s 2025 Sustainability Data and Disclosures (“the Report”). This assurance statement applies to the Subject Matter included within the scope of work described below.

This information and its presentation in the Report are the sole responsibility of the management of Baxter. Apex was not involved in the drafting of the Report. Our sole responsibility was to provide independent assurance on the accuracy of the Subject Matter. This marks the 16th year for which we have provided assurance.

Scope of Work

The scope of our work was reasonable-level assurance of the following information included within the Report for the period January 1, 2025 to December 31, 2025 (the “Subject Matter”).

- Information included in the following sections of the Report:
 - Climate Change
 - *Greenhouse gas (GHG) emissions verification is documented under a separate verification opinion declaration.*
- Related disclosure items⁵⁴ included in the Climate Change section, including:
 - GHG Emissions - Scope 1, Scope 2 (location-based and market-based), Air Emissions and Energy

The scope of work also included limited-level assurance of the following Subject Matter:

- Information and related disclosure items included in the following sections of the Report:
 - Climate Change (Scope 3 emissions and Environmental Compliance)
 - *GHG emissions verification is documented under a separate verification opinion declaration.*
 - Employee Health and Safety
 - Environment, Health, Safety and Sustainability Governance
 - Supply Chain Management⁵⁵
 - Sustainable Products and Innovation
 - Waste Management
 - Water Stewardship

Our assurance does not extend to any other information included in the Report.

Reporting Boundaries

The following are the boundaries Baxter used for reporting sustainability data:

- Operational control
- Worldwide

Reporting Criteria

The Subject Matter needs to be read and understood together with Baxter’s internal reporting requirements for facility environmental, health, safety and sustainability performance, as well as information described in the text, data tables and notes of the Report.

Limitations and Exclusions

Excluded from the scope of our work is any verification of information relating to:

- Activities outside the defined assurance period, which is the 2025 calendar year
- Positional statements (expressions of opinion, belief, aim or future intention) by Baxter and statements of future commitment
- Any financial data previously audited by an external third party
- Data and information included in sections of the Report not listed in the scope of work above

This assurance engagement relies on a risk-based selected sample of sustainability data and the associated limitations that this entails. This independent statement should not be relied upon to detect all errors, omissions or misstatements that may exist.

Responsibilities

The preparation and presentation of the Subject Matter in the Report are the sole responsibility of the management of Baxter. Apex was not involved in the drafting of the Report or of the Reporting Criteria. Our responsibilities were to:

- Provide independent assurance about whether the Subject Matter has been prepared in accordance with the Reporting Criteria;
- Form an independent conclusion based on the assurance procedures performed and evidence obtained; and
- Report our conclusions to the stakeholders of Baxter.

Assessment Standards

We performed our work in accordance with Apex’s standard procedures and guidelines for External Assurance of Sustainability Reports and the International Standard on Assurance Engagements (ISAE) 3000 Revised, Assurance Engagements Other than Audits or Reviews of Historical Financial Information (effective for assurance reports dated on or after Dec. 15, 2015), issued by the International Auditing and Assurance Standards Board. A materiality threshold of ±5% was set for the assurance process.

Summary of Work Performed

As part of our independent verification, our work included:

- Assessing the appropriateness of the Reporting Criteria for the Subject Matter
- Conducting interviews with relevant Baxter personnel who are responsible for collecting and reporting performance data and other Subject Matter
- Reviewing documentary evidence provided by Baxter
- Reviewing Baxter’s systems for quantitative data aggregation and analysis during meetings with personnel in Baxter’s Deerfield, Illinois office
- Assessing assumptions made and the data scope and reporting boundaries
- Auditing consolidated performance data, including review of a sample of data-to-source documentation
- Auditing a selection of the Subject Matter to the corresponding source documentation
- Auditing performance data and processes during in-person audits of operating sites located in Round Lake, Illinois; Braine-l’Allued, Belgium; Jayuya, Puerto Rico; Cleveland, Mississippi; São Paulo, Brazil; and Baxter Qiaoguang (BQ), China
- Assessing the disclosure and presentation of the Subject Matter with emphasis on principles of accuracy, accessibility, balance, clarity, comparability, reliability and timeliness and to ensure consistency with the Reporting Criteria

54. Disclosure items listed throughout the statement refer to the quantitative data points and metrics that are presented throughout the Report.

55. Supply Chain Management disclosure items related to SASB were not included in the assurance engagement.

Conclusion

On the basis of our methodology and the activities described above, it is our opinion that the Subject Matter within assured sections and related disclosure items including the Climate Change (GHG Emissions - Scope 1, Scope 2 [location-based and market-based], Air Emissions and Energy) section:

- Is presented in accordance with the Reporting Criteria and is, in all material respects, fairly stated
- Is presented in a clear, understandable and accessible manner
- Allows readers to form a balanced opinion of Baxter’s activities and performance during calendar year 2025

Also, on the basis of our methodology and the activities described above:

- Nothing has come to our attention to indicate that the data and information related to the Climate Change – Scope 3 emissions and Environmental Compliance; Employee Health and Safety; Environment, Health, Safety and Sustainability Governance; Supply Chain Management; Sustainable Products and Innovation; Waste Management; and Water Stewardship sections of the Report are inaccurate or that the information is not fairly stated.
- It is also our opinion that Baxter has established appropriate systems for the collection, aggregation, analysis and review of the Subject Matter.

Additional Commentary

During the assurance process, Apex observed that Baxter continues to improve its overall data collection and reporting processes at the site and corporate levels. Opportunities for improving facility-level data collection, reporting and procedural documentation at some facilities were noted. In addition, there are opportunities for improvements to processes for compilation of corporate environmental data.

We recommend that Baxter corporate personnel continue to support individual facility personnel with collection and consolidation of site-specific metrics that are included in reporting.

Statement of Independence, Integrity and Competence

Apex is an independent professional services company that specializes in health, safety, social and environmental management services, including assurance, with more than 30 years’ history in providing these services.

Apex has implemented a Code of Ethics across the business to maintain high ethical standards among staff in their day-to-day business activities.

No member of the assurance team has a business relationship with Baxter International Inc., or its directors or managers, beyond that required of this assignment. We have conducted this verification independently, and there has been no conflict of interest.

The assurance team has extensive experience in conducting assurance on health, safety, social, environmental and ethical information, systems and processes. The team has more than 20 years’ combined experience in this field and an excellent understanding of Apex’s standard methodology for the assurance of sustainability-related assertions.



Lindsey Gates
Apex Companies, LLC
Lakewood, Colorado

June 10, 2026



Trevor Donaghu
Apex Companies, LLC
Pleasant Hill, California

Forward-Looking Statements

This report includes forward-looking statements concerning Baxter, including with respect to compliance, future performance, our sustainability commitments and targets and related underlying efforts, as well as other plans and initiatives. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company is exposed to risks as a result of its strategic actions; the company may not achieve the anticipated benefits of its significant transactions, including the sale of its Kidney Care business and its acquisition of Hill-Rom Holdings, Inc.; the company's significant indebtedness requires it to use a substantial amount of its cash flow for debt service and constrains the company's ability to pursue growth strategies and advance its R&D capabilities; there is substantial competition in the product markets in which the company operates and the risk of declining demand and pricing pressures could adversely affect the company's business, results of operations, financial condition and cash flows; the company may be unable to successfully introduce or monetize new and existing products or services or keep pace with changing consumer preferences and needs or advances in technology; the company may not achieve its financial goals; the company has experienced disruptions in its supply chain; global economic conditions, including inflation, have adversely affected, and could continue to adversely affect, the company's operations; the company may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions; continued consolidation in the healthcare industry or additional governmental controls exerted over pricing and access in key markets could lead to increased demands for price concessions or limit or eliminate the company's ability to sell to certain of its significant market segments; the company's operating results and financial condition have fluctuated and may in the future continue to fluctuate; management transition creates uncertainties, and the company may experience difficulties in managing such transitions, including attracting and retaining key employees; changes in foreign currency exchange rates and interest rates have had, and may in the future have, an adverse effect on the company's results of operations, financial condition, cash flows and liquidity; the company is subject to risks associated with doing business globally, including changes in tariffs and trade policies and treaties (including with respect to the validity of previously issued tariffs and the availability of any related refunds) as well as the ongoing Iran conflict and other geopolitical events; future material impairments in the value of the company's goodwill, intangible assets and other long-lived assets would negatively affect the company's operating results; segments of the company's business are significantly dependent on major contracts with group purchasing organizations, integrated delivery networks and certain other distributors and purchasers; the company may be unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price; the company may experience manufacturing, sterilization, supply or distribution difficulties; the company has experienced and may continue to experience issues with quality management or product quality, including with respect to **Novum IQ** Large Volume Pump; the company may experience breaches and breakdowns affecting its information technology systems or protected information, including from obsolescence, cybersecurity breaches and data leakage; the company is exposed to risks associated with incorporating AI, machine learning and other emerging technologies into our products, services and operations; a portion of the company's workforce is unionized, and the company could face labor disruptions that would interfere with its operations; the effects of climate change, including legal, regulatory or

market measures related to climate change and other sustainability topics, could adversely affect the company's business, results of operations, financial condition and cash flows; the company's commitments, goals, activities and disclosures related to sustainability and corporate responsibility matters, and the perception of the company's activities in these areas, may fail to satisfy the differing expectations of key stakeholders on these matters; the company is subject to laws and regulations globally, and its failure to comply with rapidly changing and increasingly divergent expectations of regulators in different jurisdictions could adversely impact the company; if reimbursement or other payment for our current or future products is reduced or modified in the United States or in foreign countries, or there are changes to policies with respect to pricing, taxation or rebates, the company's business could suffer; increasing regulatory focus on, and expanding laws relating to, privacy, AI and cybersecurity could impact the company's business and expose it to increased liability; the company is party to a number of pending lawsuits and other disputes which may adversely impact it; the company could be subject to fines or damages and possible exclusion from participation in federal or state healthcare programs if it fails to comply with the laws and regulations applicable to its business; if the company is unable to protect or enforce its patents or other proprietary rights, or if the company becomes subject to claims or litigation alleging infringement of the patents or other proprietary rights of others, the company's competitiveness and business prospects may be materially damaged; changes in tax laws or exposure to additional income tax liabilities may have a negative impact on the company's operating results; the company's Amended and Restated Bylaws could limit its stockholders' ability to choose their preferred judicial forum for disputes with the company or its directors, officers or employees; the company recently decreased its quarterly dividend to \$0.01 per share and cannot guarantee that it will increase the amount of dividends it pays, or that it will not cease paying dividends; the company's common stock price has fluctuated significantly and may continue to do so; and other risks discussed in Baxter's most recent filings on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.



Baxter International Inc.

One Baxter Parkway

Deerfield, Illinois 60015

USA

www.baxter.com

© Baxter International Inc., 2026. All rights reserved.

References in this report to Baxter are intended to refer collectively to Baxter International Inc. and its U.S. and international subsidiaries.

Baxter, BardyDx, BeWell@Baxter, DeviceBridge, Dose IQ, ExactaMix, Hemopatch, HR 900, ICNet, Life2000, Novum IQ, RetinaVue, Viaflo and Viaflex are trademarks of Baxter International Inc. or its subsidiaries.

Apex is a trademark of Apex Companies, LLC.

MiniCap is a trademark of Vantive Health LLC or its affiliates.

Any other trademarks, product names or brand images appearing herein are the property of their respective owners.